Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Abstract

The instant disclosure provides antibodies and antigen-binding fragments that can bind to a RSV and / or MPV fusion glycoprotein and can neutralize a RSV and / or MPV infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent a RSV and / or MPV infection.

Description

[0001]BROADLY NEUTRALIZING ANTIBODIES AGAINST RSV AND MPV PARAMYXOVIRUSES REFERENCE TO AN ELECTRONIC SEQUENCE LISTING 5 The contents of the electronic sequence listing (368564_45102_SLxml; Size 344,064 bytes; Date of Creation: July 9, 2024) is herein incorporated by reference in its entirety. BACKGROUND Respiratory Syncytial Virus (RSV) and Metapneumovirus (MPV) are common cold 10 viruses belonging to the family of paramyxovirus that share target population and represent a major health problem in newborns and immunocompromised patients. RSV is the major cause of acute respiratory tract disease in infants and adults across the globe. Between 0.5% and 3.2% of children with RSV infection require hospitalization (Thompson et al., JAMA: The Journal of the American Medical Association 289: 179-186 15 (2003)), and 5% to 10% of children have prolonged severe infection, a factor believed to be predisposing to wheezing and asthma-like symptoms later in childhood. Immunity to RSV appears to be short-lived, thus re-infections are frequent (Ogra, Paediatric Respiratory Reviews 5 Suppl A:S119-126 (2003)). The human MPV was isolated for the first time in 2001 and is now recognized to be the 20 second major cause of acute respiratory tract disease in infants and adults; it is estimated that it infects over 50% of infants by two years of age and almost all children by five years. MPV accounts for roughly 5 to 15% of respiratory disease in hospitalized young children (Alto, The Journal of the American Board of Family Practice / American Board of Family Practice 17:466-469 (2004); Williams et al., N Engl J Med 350:443-450 (2004)). Infection with MPV is 25 a significant burden of disease in at-risk premature infants, chronic lung disease of prematurity, congestive heart disease, and immunodeficiency (Martino et al., Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 11:781-796 (2005)). Co-infections with MPV and RSV may be common given their prevalence and 30 overlapping winter epidemics. Although it is unclear whether synergistic pathology can occur between these two viruses, exacerbations leading to particularly severe respiratory tract disease were observed in some children co-infected with MPV and RSV (Greensill, Emerging Infectious Diseases 9:372 (2003)).160587589.11 RSV, which belongs to the Pneumovirus genus of the subfamily Pneumoviriniae, and MPV, which belongs to the Metapneumovirus genus of the subfamily Pneumoviriniae, have some similarities in their genetic structure, though MPV lacks the non-structural genes NS1 and NS2 found in RSV. The RSV and MPV envelopes contain three virally encoded transmembrane 5 surface glycoproteins: the major attachment glycoprotein G, the fusion glycoprotein F, and the small hydrophobic SH protein. Although the RSV and MPV envelopes contain proteins that are functionally similar, it is important to note, however, that the F proteins of RSV and MPV share only 33% amino acid sequence identity. The RSV and MPV F glycoproteins direct viral penetration by fusion between the 10 virion envelope and the host cell plasma membrane. Later in infection, F protein expressed on the cell surface can mediate fusion with neighboring cells to form syncytia (Collins et al., PNAS 81:7683-7687 (1984)). In both cases, the N-terminus of the F subunit that is created by proteolytic cleavage and contains hydrophobic stretch of amino acids, called the fusion peptide, inserts directly into the target membrane to initiate fusion. After binding to the target cell and 15 subsequent activation, the metastable pre-fusion F protein undergoes a series of structural rearrangements that result in the insertion of the fusion peptide into the target cell membrane, followed by the formation of a stable helical bundle that forms as the viral and cell membranes are opposed. These structural changes lead to the formation of a stable post-fusion F protein. Vaccines for RSV or MPV infection are currently not available. 20 Evidence for the role of serum antibodies in protection against RSV virus has emerged from epidemiological as well as animal studies. In infants, titers of maternally transmitted antibodies correlate with resistance to serious disease (Glezen et al., The Journal of Pediatrics 98:708-715 (1981)), and in adults, incidence and severity of lower respiratory tract involvement is diminished in the presence of high levels of serum RSV neutralizing antibodies (Mcintosh et 25 al., The Journal of Infectious Diseases 138:24-32 (1978)). A monoclonal antibody, Palivizumab (Synagis), is registered for the prevention of RSV infection in premature newborns. Palivizumab, however, is not always effective in preventing RSV infection and is not effective therapeutically. Further, prolonged pulmonary replication of RSV in the presence of Palivizumab is followed in animals by the appearance of resistant virus strains (Zhao and 30 Sullender, Journal of Virology 79:3962-3968 (2005)). Currently there are no monoclonal antibodies for the treatment or prevention of MPV infection. The lack of a good working animal model for the most severe forms of RSV infection is related to the fact that RSV and MPV are host-restricted Pneumovirus pathogens. The development of new drugs for the therapy of RSV and MPV infections has been160587589.12 hampered by the lack of an animal model able to recapitulate all the symptoms and severity of the human disease. Indeed, RSV and MPV are not natural mouse pathogens and induce only a limited, minimally symptomatic, and rapidly aborted primary infection in response to a massive, non-physiologic inoculum of the virus. Pneumonia virus of mice (PVM) is a natural 5 rodent Pneumovirus pathogen which belongs to the same family, subfamily and genus (Pneumovirus) of human and bovine RSV. The PVM F protein shares only 40% amino acid identity with human RSV F protein, but has the same genetic organization with the exception of the M2-L overlap which is present in RSV but absent in PVM. The infection by the natural mouse pathogen PVM replicates many 10 of the signs and symptoms of the most severe forms of RSV as it occurs in human infants. PVM infection is characterized by rapid virus replication accompanied by a massive inflammatory response that leads to respiratory failure and death (Rosemberg and Domachowske, Immunology Letter 118:6-12 (2008)). PVM infection in mice is therefore considered to be the most relevant animal model of RSV and MPV severe infections of humans. The lack of 15 preventive treatment for MPV infection and of vaccines against RSV and MPV infections, as well as the therapeutic inefficacy of Palivizumab, highlight the need for new preventive and therapeutic agents against these prominent human pathogens. BRIEF DESCRIPTION OF THE DRAWINGS 20 Figure 1 shows the results of a MPV ADCC assay for various antibodies, including the antibody MPK190, an ancestor of engineered antibodies of the present disclosure. Figures 2A-2C show i) the results of RSV-based ADCP assays (Figure 2A and Figure 2B), and ii) the results of a MPV-based ADCP assay (Figure 2C) for various antibodies, including the MPK190 antibody. 25 Figure 3 shows the results of a RSV escape mutants assay for various antibodies, including the MPK190 antibody. Figure 4 shows the results of a MPV escape mutants assay for various antibodies, including the MPK190 antibody. Figure 5 shows the results of the MPK190 antibody and comparator antibody 30 nirsevimab on weight loss in RSV-infected mice. Figure 6 shows the results of the MPK190 antibody and comparator antibody nirsevimab on survival in RSV-infected mice. Figure 7 shows the results of MPK51 and the MPK190 antibody and comparator antibody nirsevimab on weight loss and survival in RSV-infected mice.160587589.13 Figure 8 shows the results of low doses of the MPK190 antibody and comparator antibody nirsevimab on weight loss and survival in RSV-infected mice. Figure 9 shows a heat map of antibodies, including the MPK190 antibody, binding to RSV A and RSV B strains as assessed by fluorescence-activated cell sorting (FACS). 5 Figure 10 shows a heat map of variant antibodies, including the MPK190 antibody, binding to MPV strains as assessed by FACS. Figure 11 shows the results of the MPK190 antibody incubated with RSV A-GFP added to HEp-2 and LLC-MK2 cells after 8 cycles of reinfection. Figure 12 shows the results of palivizumab incubated with RSV A-GFP added to HEp- 10 2 and LLC-MK2 cells after 8 cycles of reinfection. Figure 13 shows the results of the MPK190 antibody incubated with MPV A2-GFP added to HEp-2 and LLC-MK2 cells after 8 cycles of reinfection. Figure 14 shows a graph of mAb concentration for the MPK190 antibody, and MPK51, MPK104, and MPK77 versus number of days in an in vivo PK study. 15 Figure 15 shows IC50 graphs of neutralization of mouse adapted RSV clone by the MPK190 antibody, as well as by antibodies MPK104, MPK51, MPK77, and MEDI8897, in RSV-infected mice. Figure 16 shows lack of polyreactivity of selected MPK variant antibodies including the MPK190 antibody as well as the variant MPK190-v1.1 and MPK190-v1.3 antibodies, when 20 tested in a Euroimmun 1522-2010 slide assay. MPK wild type antibodies ("WT") were included as a comparator. The antibodies of the present disclosure were engineered starting from MPK190-v1.3. Figures 17A-17C show binding of variant antibodies MPK190-v1.1, MPK190-v1.3, and other variants MPK190-v3.1, MPK190-v3.3, MPK190-v4.1, and MPK190-v4.3 to RSV-F 25 (Figure 17A), MPV-F (Figure 17B), and MPV-F D280N (Figure 17C), as measured using BLI. Figures 18A-18C show binding of variants of the MPK190 antibody after forced deamidation to RSV-F (Figure 18A), MPV-F (Figure 18B), and MPV-F D280N (Figure 18C), as measured using BLI. 30 Figure 19 shows binding of variants of the MPK190 antibody to MPV-F D280N after forced deamidation of MPK-190, as measured using BLI. Figure 20 shows lack of polyreactivity of selected MPK190 variant antibodies, including MPK190-v1.1 and MPK190-v1.3 antibodies as well as other variant MPK190 antibodies, when tested in a Euroimmun 1522-2010 slide assay.160587589.14 Figures 21A-21D show results of binding (FACS) of MPK antibody variants including MPK 190, MPK190-v1.1 and MPK190-v1.3 antibodies as well as other variant MPK190 antibodies, to RSV F TM WT (Figure 21A), MPV F D280N (Figure 21B), MPV F (Figure 21C), and mock binding (Figure 21D). 5 Figures 22A-22C shows results of a PK study on MPK190 antibody tested for binding to RSV F (Figure 22A), MPV F (Figure 22B), and D280N F (Figure 22C) on transfected cells. Figures 23A and 23B show MPK190-v1.3 antibody in activation of FcγRIIa (ADCP) and FcRγIIIa (ADCC), and in inducing NK cell killing (ADCC), compared to nirsevimab, in RSV A-infected Hep2 cells (Figure 23A) and in MPV A1-infected Hep2 cells (Figure 23B) 10 (NK-mediated cell killing not shown in Figure 23B). Figures 24A and 24B show the results of MPK190-v1.3 antibody, MEDI18897, MPE8-v3, and comparator antibody palivizumab at 2 mg / kg (Figure 24A) and at 0.5 mg / kg (Figure 24B) on weight loss in RSV-infected mice. Figures 25A and 25B show the results of MPK190-v1.3, MEDI18897, MPE8-v3, and 15 comparator antibody palivizumab at 2 mg / kg (Figure 25A) and at 0.5 mg / kg (Figure 25B) on survival in RSV-infected mice. Figures 26A-26C summarizes mutations, made relative to MPK190-v1.3 aka ML- M190-1.3, to produce variant antibodies. The amino acid numbering is relative to the position within MPK190-v1.3 Fd (SEQ ID NO.:97) or light chain (SEQ ID NO.:93) sequence. 20 Figures 27A and 27B show the results of MPK190-v1.3, MEDI18897, MPE8-v3, and comparator antibody palivizumab at 2 mg / kg (Figure 27A) and at 0.5 mg / kg (Figure 27B) on weight loss in RSV-infected mice. Figures 28A and 28B show the results of MPK190-v1.3, MEDI18897, MPE8-v3, and comparator antibody palivizumab at 2 mg / kg (Figure 28A) and at 0.5 mg / kg (Figure 28B) on 25 survival in RSV-infected mice. Figures 29A and 29B show the effects of MPK176, MPK201, and MPK65-v2, and comparator antibodies at 2 mg / kg (Figure 29A and Figure 29C) and at 0.5 mg / kg (Figure 29B and Figure 29D) on weight change and survival in RSV-infected mice. Figure 30A and Figure 30B show the effects of various doses of MPK190-v1.3 and 30 comparator antibodies on viral titers in cotton rats exposed to RSV A (Figure 32A) or RSV B (Figure 30B). Figure 31A and Figure 31B show the effects of various doses of MPK190-v1.3 and comparator antibodies on viral titers in cotton rats exposed to MPV. Figure 32A and Figure 32B show results of neutralization screenings of160587589.15 MPV / RSV antibodies, including MPK190-v1.3 (designated as MPK 190 in the figure) against a MPV A strain and a MPV B strain. Figure 33 shows a heat map of RSV-only antibodies and their binding to a panel of F proteins of recently circulating RSV B strains. 5 Figures 34A (IC50) and 34B (IC90) show results of neutralization screenings of MPV / RSV antibodies, including MPK190-v1.3, and RSV-only antibodies, including MPK102 and MPK176, against various RSV A and RSV B lab-adapted and circulating strains. Figures 35A-35E show luminescence of FcγRIIIa (F158 allele) using RSV-FA- transfected Expi293 target cells (Figure 35A), RSV-FB-transfected Expi293 target cells 10 (Figure 35B), MPV-FA-transfected Expi293 target cells (Figure 35D), or MPV-FB-transfected Expi293 target cells (Figure 35E), and antibody-dependent killing of RSV-A2-transfected Hep- 2 cells (Figure 37C. Legend for Figures 35A-35C is shown in Figure 35C and legend for Figures 35D-35E is shown in Figure 35E. Figure 36A and Figure 36B shows neutralization data (Figure 36A) and summary 15 graphs (Figure 36B) data for Fab fragments of RSV-only antibodies and MPK190-v1.3 for RSV A (upper graphs) and MPV (lower graphs). Figure 37 shows a summary of effector functions of MPK190-v1.3 and RSV-only antibodies. Figure 38 shows the results of neutralization testing of MPK190-v1.3 and various 20 comparator antibodies against representatives of all four MPV subtypes. Figure 39 shows results of MPK190-v1.3 neutralization of a representative MPV B1 strain virus (NL / 1 / 99). Figure 40 shows neutralization of various MPV subtypes by MPK190-v1.3. Figure 41 shows the results of ADCC testing using Hep-2 cells infected with the RSV 25 A2 strain (MOI 2.5, NK 10:1) and MPK190. Figures 42A-42F show synergism between MPK190 and selected RSV-only antibodies for neutralization of RSV A (Figures 42A-42C) or RSV F (Figures 42D-42F). Figure 43 shows predicted RSV F binding of MPK190-v1.3 to RSVF as compared to binding of comparator antibodies MPE8 and MPH12. 30 Figures 44A-44E show luminescence of FcγRIIIa (V158 allele) using RSV-FB- transfected Expi293 target cells for various combinations of MPK190-v1.2 and RSV-only antibodies. Figure 45 shows AUC results for the data of Figures 44A-44E. Figure 46, as described in Example 33, shows a summary graph of RSV160587589.16 A2 neutralization data for individual antibodies as well as combinations of RSV-only antibodies with MPK190-v1.3 from Figures 44A-44E. Figure 47 shows a summary of neutralization data for RSV A2 for combinations of RSV-only antibodies with MPK190-v1.3. 5 Figure 48 shows the antigen-binding site of MPK190-v1.3. Blue indicates a positive patch, and yellow indicates a hydrophobic patch. Figure 49 shows pharmacokinetic testing results for MPK190 variant antibodies as compared to MPK190-v1.3 in FcRN KO mice. Figure 50 presents KD ranges for MPK190-v1.3 variants for various RSV and MPK F 10 proteins. Figure 51 presents binding efficiency assay results for MPK190-v1.3 variants for various recently circulating and / or common RSV and MPK strains. Figure 52 presents results from in vitro viral neutralization assays conducted using selected R2-# variants as compared to MPK190-v1.3. 15 Figure 53 presents pharmacokinetic testing results for multiple MPK190-v1.3 variants with YTE mutations compared to MPK190-v36.21 with the LS mutation. Figure 54 presents a table comparing KD, potency, and biophysical properties of several MPK190-v1.3 variants with LS Fc mutation. Figure 55A presents a table with PK parameters of several MPK190-v1.3 variants 20 compared to MPK190-v36.21 with the LS mutation. Figure 55B presents concentration of several MPK190-v1.3 variants compared to MPK190-v36.21 (R2-118) with the LS mutation over time. Figure 56 presents C / T plots of MPK190-v1.3-LS, MPK190-v1.3-YTE, and MPK190- v20.6-LS antibodies. 25 Figure 57 presents NCA PK parameters of MPK190-v1.3-LS, MPK190-v1.3-YTE, and MPK190-v20.6-LS antibodies. Figure 58 presents biocomp analysis parameters of MPK190-v1.3-LS, MPK190-v1.3- YTE, and MPK190-v20.6-LS antibodies. 30 DETAILED DESCRIPTION Provided herein are antibodies and antigen-binding fragments that can bind to and, in some embodiments, potently neutralize infection by RSV and / or MPV. Also provided are polynucleotides that encode the antibodies and antigen-binding fragments, vectors, host cells, and related compositions, as well as methods of using the antibodies, nucleic acids,160587589.17 vectors, host cells, and related compositions to treat (e.g., reduce, delay, eliminate, or prevent) a RSV and / or MPV infection in a subject and / or in the manufacture of a medicament for treating a RSV and / or MPV infection in a subject. In some embodiments, antibodies or antigen-binding fragments thereof of the present 5 disclosure may be able to treat infection of MPV with a D280N mutation, as well as other variants of MPV. The D280N mutation has proven difficult to treat with other potential therapeutics. In other embodiments, antibodies or antigen-binding fragments thereof of the present disclosure may promote survival and decrease weight loss in RSV-infected patients at least as 10 well as nirsevimab, an anti-RSV antibody that has had favorable clinical trial results. In some embodiments, antibodies or antigen-binding fragments thereof of the present disclosure may provide a uniquely broad array of treatment and protection to patients, without the need for complex diagnostics to determine if an infection is RSV, MPV, or which MPV, because the antibody or antigen-binding fragment may be able to effectively bind the F protein 15 of both RSV and MPV, even if the D280N mutation is present in MPV. Prior to setting forth this disclosure in more detail, it may be helpful to an understanding thereof to provide definitions of certain terms to be used herein. Additional definitions are set forth throughout this disclosure. In the present description, any concentration range, percentage range, ratio range, or 20 integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Also, any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated. As used herein, the term "about" means ± 25 20% of the indicated range, value, or structure, unless otherwise indicated. It should be understood that the terms "a" and "an" as used herein refer to "one or more" of the enumerated components. The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms "include," "have," and "comprise" are used synonymously, which terms and variants thereof are intended 30 to be construed as non-limiting. "Optional" or "optionally" means that the subsequently described element, component, event, or circumstance may or may not occur, and that the description includes instances in which the element, component, event, or circumstance occurs and instances in which they do not.160587589.18 In addition, it should be understood that the individual constructs, or groups of constructs, derived from the various combinations of the structures and subunits described herein, are disclosed by the present application to the same extent as if each construct or group of constructs was set forth individually. Thus, selection of particular structures or particular 5 subunits is within the scope of the present disclosure. The term "consisting essentially of" is not equivalent to "comprising" and refers to the specified materials or steps of a claim, or to those that do not materially affect the basic characteristics of a claimed subject matter. For example, a protein domain, region, or module (e.g., a binding domain) or a protein "consists essentially of" a particular amino acid sequence 10 when the amino acid sequence of a domain, region, module, or protein includes extensions, deletions, mutations, or a combination thereof (e.g., amino acids at the amino- or carboxy- terminus or between domains) that, in combination, contribute to at most 20% (e.g., at most 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2% or 1%) of the length of a domain, region, module, or protein and do not substantially affect (i.e., do not reduce the activity by more than 50%, such 15 as no more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%) the activity of the domain(s), region(s), module(s), or protein (e.g., the target binding affinity of a binding protein). As used herein, "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the 20 genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ- carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α-carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R 25 groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. As used herein, "mutation" refers to a change in the sequence of a nucleic acid 30 molecule or polypeptide molecule as compared to a reference or wild-type nucleic acid molecule or polypeptide molecule, respectively. A mutation can result in several different types of change in sequence, including substitution, insertion or deletion of nucleotide(s) or amino acid(s).160587589.19 A "conservative substitution" refers to amino acid substitutions that do not significantly affect or alter binding characteristics of a particular protein. Generally, conservative substitutions are ones in which a substituted amino acid residue is replaced with an amino acid residue having a similar side chain. Conservative substitutions include a substitution found in 5 one of the following groups: Group 1: Alanine (Ala or A), Glycine (Gly or G), Serine (Ser or S), Threonine (Thr or T); Group 2: Aspartic acid (Asp or D), Glutamic acid (Glu or Z); Group 3: Asparagine (Asn or N), Glutamine (Gln or Q); Group 4: Arginine (Arg or R), Lysine (Lys or K), Histidine (His or H); Group 5: Isoleucine (Ile or I), Leucine (Leu or L), Methionine (Met or M), Valine (Val or V); and Group 6: Phenylalanine (Phe or F), Tyrosine (Tyr or Y), Tryptophan 10 (Trp or W). Additionally or alternatively, amino acids can be grouped into conservative substitution groups by similar function, chemical structure, or composition (e.g., acidic, basic, aliphatic, aromatic, or sulfur-containing). For example, an aliphatic grouping may include, for purposes of substitution, Gly, Ala, Val, Leu, and Ile. Other conservative substitutions groups include: sulfur-containing: Met and Cysteine (Cys or C); acidic: Asp, Glu, Asn, and Gln; small 15 aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, and Gly; polar, negatively charged residues and their amides: Asp, Asn, Glu, and Gln; polar, positively charged residues: His, Arg, and Lys; large aliphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and large aromatic residues: Phe, Tyr, and Trp. Additional information can be found in Creighton (1984) Proteins, W.H. Freeman and Company. 20 As used herein, "protein" or "polypeptide" refers to a polymer of amino acid residues. Proteins apply to naturally occurring amino acid polymers, as well as to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, and non-naturally occurring amino acid polymers. Variants of proteins, peptides, and polypeptides of this disclosure are also contemplated. In certain 25 embodiments, variant proteins, peptides, and polypeptides comprise or consist of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% identical to an amino acid sequence of a defined or reference amino acid sequence as described herein. "Nucleic acid molecule" or "polynucleotide" or "polynucleic acid" refers to a polymeric 30 compound including covalently linked nucleotides, which can be made up of natural subunits (e.g., purine or pyrimidine bases) or non-natural subunits (e.g., morpholine ring). Purine bases include adenine, guanine, hypoxanthine, and xanthine, and pyrimidine bases include uracil, thymine, and cytosine. Nucleic acid molecules include polyribonucleic acid (RNA), which includes mRNA, microRNA, siRNA, viral genomic RNA, and synthetic RNA, and160587589.110 polydeoxyribonucleic acid (DNA), which includes cDNA, genomic DNA, and synthetic DNA, either of which may be single or double stranded. If single-stranded, the nucleic acid molecule may be the coding strand or non-coding (anti-sense) strand. A nucleic acid molecule encoding an amino acid sequence includes all nucleotide sequences that encode the same amino acid 5 sequence. Some versions of the nucleotide sequences may also include intron(s) to the extent that the intron(s) would be removed through co- or post-transcriptional mechanisms. In other words, different nucleotide sequences may encode the same amino acid sequence as the result of the redundancy or degeneracy of the genetic code, or by splicing. Variants of nucleic acid molecules of this disclosure are also contemplated. Variant 10 nucleic acid molecules are at least 70%, 75%, 80%, 85%, 90%, and are preferably 95%, 96%, 97%, 98%, 99%, or 99.9% identical a nucleic acid molecule of a defined or reference polynucleotide as described herein, or that hybridize to a polynucleotide under stringent hybridization conditions of 0.015M sodium chloride, 0.0015M sodium citrate at about 65-68ºC or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at about 42ºC. 15 Nucleic acid molecule variants retain the capacity to encode a binding domain thereof having a functionality described herein, such as binding a target molecule. "Percent sequence identity" refers to a relationship between two or more sequences, as determined by comparing the sequences. Preferred methods to determine sequence identity are designed to give the best match between the sequences being compared. For example, the 20 sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment). Further, non-homologous sequences may be disregarded for comparison purposes. The percent sequence identity referenced herein is calculated over the length of the reference sequence, unless indicated otherwise. Methods to determine sequence identity and similarity can be found 25 in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using a BLAST program (e.g., BLAST 2.0, BLASTP, BLASTN, or BLASTX). The mathematical algorithm used in the BLAST programs can be found in Altschul et al., Nucleic Acids Res.25:3389-3402, 1997. Within the context of this disclosure, it will be understood that where sequence analysis software is used for analysis, the 30 results of the analysis are based on the "default values" of the program referenced. "Default values" mean any set of values or parameters which originally load with the software when first initialized. The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally160587589.111 occurring nucleic acid or polypeptide present in a living animal is not isolated, but the same nucleic acid or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such nucleic acid could be part of a vector and / or such nucleic acid or polypeptide could be part of a composition (e.g., a cell lysate), and still be isolated in that 5 such vector or composition is not part of the natural environment for the nucleic acid or polypeptide. The term "gene" means the segment of DNA or RNA involved in producing a polypeptide chain; in certain contexts, it includes regions preceding and following the coding region (e.g., 5’ untranslated region (UTR) and 3’ UTR) as well as intervening sequences 10 (introns) between individual coding segments (exons). A "functional variant" refers to a polypeptide or polynucleotide that is structurally similar or substantially structurally similar to a parent or reference compound of this disclosure, but differs slightly in composition (e.g., one base, atom or functional group is different, added, or removed), such that the polypeptide or encoded polypeptide is capable of performing at least 15 one function of the parent polypeptide with at least 50% efficiency, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% level of activity of the parent polypeptide. In other words, a functional variant of a polypeptide or encoded polypeptide of this disclosure has "similar binding," "similar affinity" or "similar activity" when the functional variant displays no more than a 50% reduction in performance in a 20 selected assay as compared to the parent or reference polypeptide, such as an assay for measuring binding affinity (e.g., BIACORE® or tetramer staining measuring an association (Ka) or a dissociation (KD) constant). As used herein, a "functional portion" or "functional fragment" refers to a polypeptide or polynucleotide that comprises only a domain, portion or fragment of a parent or reference 25 compound, and the polypeptide or encoded polypeptide retains at least 50% activity associated with the domain, portion or fragment of the parent or reference compound, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% level of activity of the parent polypeptide, or provides a biological benefit (e.g., effector function). A "functional portion" or "functional fragment" of a polypeptide or encoded polypeptide of this 30 disclosure has "similar binding" or "similar activity" when the functional portion or fragment displays no more than a 50% reduction in performance in a selected assay as compared to the parent or reference polypeptide (preferably no more than 20% or 10%, or no more than a log difference as compared to the parent or reference with regard to affinity).160587589.112 As used herein, the term "engineered," "recombinant," or "non-natural" refers to an organism, microorganism, cell, nucleic acid molecule, or vector that includes at least one genetic alteration or has been modified by introduction of an exogenous or heterologous nucleic acid molecule, wherein such alterations or modifications are introduced by genetic engineering 5 (i.e., human intervention). Genetic alterations include, for example, modifications introducing expressible nucleic acid molecules encoding functional RNA, proteins, fusion proteins or enzymes, or other nucleic acid molecule additions, deletions, substitutions, or other functional disruption of a cell’s genetic material. Additional modifications include, for example, non- coding regulatory regions in which the modifications alter expression of a polynucleotide, gene, 10 or operon. As used herein, "heterologous" or "non-endogenous" or "exogenous" refers to any gene, protein, compound, nucleic acid molecule, or activity that is not native to a host cell or a subject, or any gene, protein, compound, nucleic acid molecule, or activity native to a host cell or a subject that has been altered. Heterologous, non-endogenous, or exogenous includes genes, 15 proteins, compounds, or nucleic acid molecules that have been mutated or otherwise altered such that the structure, activity, or both is different as between the native and altered genes, proteins, compounds, or nucleic acid molecules. In certain embodiments, heterologous, non- endogenous, or exogenous genes, proteins, or nucleic acid molecules (e.g., receptors, ligands, etc.) may not be endogenous to a host cell or a subject, but instead nucleic acids encoding such 20 genes, proteins, or nucleic acid molecules may have been added to a host cell by conjugation, transformation, transfection, electroporation, or the like, wherein the added nucleic acid molecule may integrate into a host cell genome or can exist as extra-chromosomal genetic material (e.g., as a plasmid or other self-replicating vector). The term "homologous" or "homolog" refers to a gene, protein, compound, nucleic acid molecule, or activity found in or 25 derived from a host cell, species, or strain. For example, a heterologous or exogenous polynucleotide or gene encoding a polypeptide may be homologous to a native polynucleotide or gene and encode a homologous polypeptide or activity, but the polynucleotide or polypeptide may have an altered structure, sequence, expression level, or any combination thereof. A non- endogenous polynucleotide or gene, as well as the encoded polypeptide or activity, may be from 30 the same species, a different species, or a combination thereof. In certain embodiments, a nucleic acid molecule or portion thereof native to a host cell will be considered heterologous to the host cell if it has been altered or mutated, or a nucleic acid molecule native to a host cell may be considered heterologous if it has been altered with a heterologous expression control sequence or has been altered with an endogenous160587589.113 expression control sequence not normally associated with the nucleic acid molecule native to a host cell. In addition, the term "heterologous" can refer to a biological activity that is different, altered, or not endogenous to a host cell. As described herein, more than one heterologous nucleic acid molecule can be introduced into a host cell as separate nucleic acid molecules, as a 5 plurality of individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a fusion protein, or any combination thereof. As used herein, the term "endogenous" or "native" refers to a polynucleotide, gene, protein, compound, molecule, or activity that is normally present in a host cell or a subject. The term "expression", as used herein, refers to the process by which a polypeptide is 10 produced based on the encoding sequence of a nucleic acid molecule, such as a gene. The process may include transcription, post-transcriptional control, post-transcriptional modification, translation, post-translational control, post-translational modification, or any combination thereof. An expressed nucleic acid molecule is typically operably linked to an expression control sequence (e.g., a promoter). 15 The term "operably linked" refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). "Unlinked" means that the associated genetic elements 20 are not closely associated with one another and the function of one does not affect the other. As described herein, more than one heterologous nucleic acid molecule can be introduced into a host cell as separate nucleic acid molecules, as a plurality of individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a protein (e.g., a heavy chain of an antibody), or any combination thereof. When two 25 or more heterologous nucleic acid molecules are introduced into a host cell, it is understood that the two or more heterologous nucleic acid molecules can be introduced as a single nucleic acid molecule (e.g., on a single vector), on separate vectors, integrated into the host chromosome at a single site or multiple sites, or any combination thereof. The number of referenced heterologous nucleic acid molecules or protein activities refers to the number of encoding 30 nucleic acid molecules or the number of protein activities, not the number of separate nucleic acid molecules introduced into a host cell. The term "construct" refers to any polynucleotide that contains a recombinant nucleic acid molecule (or, when the context clearly indicates, a fusion protein of the present disclosure). A (polynucleotide) construct may be present in a vector (e.g., a bacterial vector, a160587589.114 viral vector) or may be integrated into a genome. A "vector" is a nucleic acid molecule that is capable of transporting another nucleic acid molecule. Vectors may be, for example, plasmids, cosmids, viruses, an RNA vector or a linear or circular DNA or RNA molecule that may include chromosomal, non-chromosomal, semi-synthetic or synthetic nucleic acid molecules. Vectors 5 of the present disclosure also include transposon systems (e.g., Sleeping Beauty, see, e.g., Geurts et al., Mol. Ther.8:108, 2003: Mátés et al., Nat. Genet.41:753, 2009). Exemplary vectors are those capable of autonomous replication (episomal vector), capable of delivering a polynucleotide to a cell genome (e.g., viral vector), or capable of expressing nucleic acid molecules to which they are linked (expression vectors). 10 As used herein, "expression vector" or "vector" refers to a DNA construct containing a nucleic acid molecule that is operably linked to a suitable control sequence capable of effecting the expression of the nucleic acid molecule in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control 15 termination of transcription and translation. The vector may be a plasmid, a phage particle, a virus, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself or deliver the polynucleotide contained in the vector into the genome without the vector sequence. In the present specification, "plasmid," "expression 20 plasmid," "virus," and "vector" are often used interchangeably. The term "introduced" in the context of inserting a nucleic acid molecule into a cell, means "transfection", "transformation," or "transduction" and includes reference to the incorporation of a nucleic acid molecule into a eukaryotic or prokaryotic cell wherein the nucleic acid molecule may be incorporated into the genome of a cell (e.g., chromosome, 25 plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA). In certain embodiments, polynucleotides of the present disclosure may be operatively linked to certain elements of a vector. For example, polynucleotide sequences that are needed to affect the expression and processing of coding sequences to which they are ligated may be 30 operatively linked. Expression control sequences may include appropriate transcription initiation, termination, promoter, and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequences); sequences that enhance protein stability; and possibly sequences that enhance protein secretion.160587589.115 Expression control sequences may be operatively linked if they are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. In certain embodiments, the vector comprises a plasmid vector or a viral vector (e.g., a 5 lentiviral vector or a γ-retroviral vector). Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as ortho-myxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g., measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e.g., 10 Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox, and canarypox). Other viruses include, for example, Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus. Examples of retroviruses include avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their 15 replication, In Fundamental Virology, Third Edition, B. N. Fields et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996). "Retroviruses" are viruses having an RNA genome, which is reverse-transcribed into DNA using a reverse transcriptase enzyme, the reverse-transcribed DNA is then incorporated into the host cell genome. "Gammaretrovirus" refers to a genus of the retroviridae family. 20 Examples of gammaretroviruses include mouse stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis viruses. "Lentiviral vectors" include HIV-based lentiviral vectors for gene delivery, which can be integrative or non-integrative, have relatively large packaging capacity, and can transduce a range of different cell types. Lentiviral vectors are usually generated following transient 25 transfection of three (packaging, envelope, and transfer) or more plasmids into producer cells. Like HIV, lentiviral vectors enter the target cell through the interaction of viral surface glycoproteins with receptors on the cell surface. On entry, the viral RNA undergoes reverse transcription, which is mediated by the viral reverse transcriptase complex. The product of reverse transcription is a double-stranded linear viral DNA, which is the substrate for viral 30 integration into the DNA of infected cells. In certain embodiments, the viral vector can be a gammaretrovirus, e.g., Moloney murine leukemia virus (MLV)-derived vectors. In other embodiments, the viral vector can be a more complex retrovirus-derived vector, e.g., a lentivirus-derived vector. HIV-1-derived vectors belong to this category. Other examples include lentivirus vectors derived from160587589.116 HIV-2, FIV, equine infectious anemia virus, SIV, and Maedi-Visna virus (ovine lentivirus). Methods of using retroviral and lentiviral viral vectors and packaging cells for transducing mammalian host cells with viral particles containing transgenes are known in the art and have been previous described, for example, in: U.S. Patent 8,119,772; Walchli et al., PLoS One 5 6:327930, 2011; Zhao et al., J. Immunol.174:4415, 2005; Engels et al., Hum. Gene Ther. 14:1155, 2003; Frecha et al., Mol. Ther.18:1748, 2010; and Verhoeyen et al., Methods Mol. Biol.506:97, 2009. Retroviral and lentiviral vector constructs and expression systems are also commercially available. Other viral vectors also can be used for polynucleotide delivery including DNA viral vectors, including, for Example adenovirus-based vectors and adeno- 10 associated virus (AAV)-based vectors; vectors derived from herpes simplex viruses (HSVs), including amplicon vectors, replication-defective HSV and attenuated HSV (Krisky et al., Gene Ther.5:1517, 1998). Other vectors that can be used with the compositions and methods of this disclosure include those derived from baculoviruses and α-viruses. (Jolly, D J.1999. Emerging Viral 15 Vectors. pp 209-40 in Friedmann T. ed. The Development of Human Gene Therapy. New York: Cold Spring Harbor Lab), or plasmid vectors (such as sleeping beauty or other transposon vectors). When a viral vector genome comprises a plurality of polynucleotides to be expressed in a host cell as separate transcripts, the viral vector may also comprise additional sequences 20 between the two (or more) transcripts allowing for bicistronic or multicistronic expression. Examples of such sequences used in viral vectors include internal ribosome entry sites (IRES), furin cleavage sites, viral 2A peptide, or any combination thereof. Plasmid vectors, including DNA-based antibody or antigen-binding fragment-encoding plasmid vectors for direct administration to a subject, are described further herein. 25 As used herein, the term "host" refers to a cell or microorganism targeted for genetic modification with a heterologous nucleic acid molecule to produce a polypeptide of interest (e.g., an antibody of the present disclosure). A host cell may include any individual cell or cell culture which may receive a vector or the incorporation of nucleic acids or express proteins. The term also encompasses progeny 30 of the host cell, whether genetically or phenotypically the same or different. Suitable host cells may depend on the vector and may include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells. These cells may be induced to incorporate the vector or other material by use of a viral vector, transformation via calcium phosphate precipitation, DEAE-dextran, electroporation, microinjection, or other methods.160587589.117 See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 2d ed. (Cold Spring Harbor Laboratory, 1989). In the context of a RSV or MPV infection, a "host" refers to a cell or a subject infected with RSV and / or MPV. 5 "Antigen" or "Ag", as used herein, refers to an immunogenic molecule that provokes an immune response. This immune response may involve antibody production, activation of specific immunologically-competent cells, activation of complement, antibody dependent cytotoxicity, or any combination thereof. An antigen (immunogenic molecule) may be, for example, a peptide, glycopeptide, polypeptide, glycopolypeptide, polynucleotide, 10 polysaccharide, lipid, or the like. It is readily apparent that an antigen can be synthesized, produced recombinantly, or derived from a biological sample. Exemplary biological samples that can contain one or more antigens include tissue samples, stool samples, cells, biological fluids, or combinations thereof. Antigens can be produced by cells that have been modified or genetically engineered to express an antigen. Antigens can also be present in an RSV and / or 15 MPV fusion glycoprotein antigen, such as present in a virion, or expressed or presented on the surface of a cell infected by RSV and / or MPV. The term "epitope" or "antigenic epitope" includes any molecule, structure, amino acid sequence, or protein determinant that is recognized and specifically bound by a cognate binding molecule, such as an immunoglobulin, or other binding molecule, domain, or protein. Epitopic 20 determinants generally contain chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three-dimensional structural characteristics, as well as specific charge characteristics. Where an antigen is or comprises a peptide or protein, the epitope can be comprised of consecutive amino acids (e.g., a linear epitope), or can be comprised of amino acids from different parts or regions of the protein that are brought into 25 proximity by protein folding (e.g., a discontinuous or conformational epitope), or non- contiguous amino acids that are in close proximity irrespective of protein folding. Antibodies, Antigen-Binding Fragments, and Compositions In one aspect, the present disclosure provides an isolated antibody, or an antigen- 30 binding fragment, that is capable of binding to a fusion glycoprotein from RSV and / or MPV and / or neutralizing RSV and / or MPV in a human subject. In certain embodiments, an antibody or antigen-binding fragment of the present disclosure associates with or unites with a fusion glycoprotein of RSV or MPV, or fusion160587589.118 glycoproteins of both RSV and MPV, while not significantly associating or uniting with any other molecules or components in a sample. In certain embodiments, an antibody or antigen-binding fragment of the present disclosure specifically binds to an RSV fusion glycoprotein (also referred to herein as "RSV-F") 5 and / or a MPV fusion glycoprotein (also referred to herein as “MPV-F"). In certain embodiments, the antibody or antigen-binding fragment is capable of binding to RSV-F in a pre-fusion conformation and, in some embodiments, also in the post-fusion conformation. Unless otherwise noted herein, binding to RSV-F refers to binding to the pre-fusion conformation. In some embodiments, the MPV-F is a wild-type protein or a protein that is wild- 10 type at D280, but contains other mutations (also referred to herein as “MPV-F D280”). However, in other embodiments, the MPV-F contains a D280N mutation (also referred to herein as “MPV-F N280” or “D280N”). In some embodiments, the MPV-F is an otherwise wild-type protein with a mutation at D280 other than N (which may, for purposes of this disclosure, be considered an MPV-F D280 if it behaves more like MPV-F with no mutation at D280, or a 15 MPV-F D280N if it behaves more like MPV-F with the D280N mutation). In some embodiments, an RSV / MPV cross-binding and / or neutralizing antibody or antigen-binding fragment of the present disclosure specifically binds to: i) both RSV-F and MPV-F D280, ii) both RSV-F and MPV-F N280, iii) and / or iii) RSV-F, MPV-F D280, or MPV-F N280. In some embodiments, an RSV-binding and / or neutralizing antibody or antigen-binding 20 fragment of the present disclosure specifically binds to RSV-F. In some embodiments, an MPV- binding and / or neutralizing antibody or antigen-binding fragment of the present disclosure specifically binds to i) MPV-F N280, ii) MPV-F D280, or iii) both MPV-F N280 and MPV-F D280. As used herein, "specifically binds" refers to an association or union of an antibody or 25 antigen-binding fragment to an antigen with an affinity or Ka(i.e., an equilibrium association constant of a particular binding interaction with units of 1 / M) equal to or greater than 105M-1(which equals the ratio of the on-rate [Kon] to the off rate [Koff] for this association reaction), while not significantly associating or uniting with any other molecules or components in a sample. Alternatively, affinity may be defined as an equilibrium dissociation constant (Kd) of a 30 particular binding interaction with units of M (e.g., 10-5M to 10-13M). Antibodies may be classified as "high-affinity" antibodies or as "low-affinity" antibodies. "High-affinity" antibodies refer to those antibodies having a Kaof at least 109M-1, at least 1010M-1, at least 1011M-1, at least 1012M-1, or at least 1013M-1. "Low-affinity" antibodies refer to those antibodies having a Kaof up to 108M-1, up to 107M-1, up to 106M-1, up to 105M-1.160587589.119 Alternatively, affinity may be defined as an equilibrium dissociation constant (Kd) of a particular binding interaction with units of M (e.g., 10-5M to 10-13M). A variety of assays are known for identifying antibodies of the present disclosure that bind a particular target, as well as determining binding domain or binding protein affinities, 5 such as Western blot, ELISA (e.g., direct, indirect, or sandwich), analytical ultracentrifugation, spectroscopy, and surface plasmon resonance (BIACORE®) analysis (see, e.g., Scatchard et al., Ann. N.Y. Acad. Sci.51:660, 1949; Wilson, Science 295:2103, 2002; Wolff et al., Cancer Res. 53:2560, 1993; and U.S. Patent Nos.5,283,173, 5,468,614, or the equivalent). Assays for assessing affinity or apparent affinity or relative affinity are also known. 10 In certain examples, binding can be determined by recombinantly expressing an RSV-F and / or a MPV-F antigen in a host cell (e.g., by transfection) and immunostaining the (e.g., fixed, or fixed and permeabilized) host cell with antibody and analyzing binding by flow cytometry (e.g., using a ZE5 Cell Analyzer (BioRad®) and FlowJo software (TreeStar). In some embodiments, positive binding can be defined by differential staining by antibody of 15 RSV-F and / or MPV-F-expressing cells versus control (e.g., mock) cells. In some embodiments an antibody or antigen-binding fragment of the present disclosure binds to RSV-F and / or MPV-F, as measured using biolayer interferometry, or by surface plasmon resonance. In some embodiments an antibody or antigen-binding fragment of the present 20 disclosure may be assessed for competitive binding against another antibody or antigen-binding fragment in using surface plasmon resonance. Certain characteristics of presently disclosed antibodies or antigen-binding fragments may be described using IC50 or EC50 values. In certain embodiments, the IC50 is the concentration of a composition (e.g., antibody) that results in half-maximal inhibition of the 25 indicated biological or biochemical function, activity, or response. In certain embodiments, the EC50 is the concentration of a composition that provides the half-maximal response in the assay. In some embodiments, e.g., for describing the ability of a presently disclosed antibody or antigen-binding fragment to neutralize infection by RSV and / or MPV, IC50 and EC50 are used interchangeably. 30 In certain embodiments, an antibody or antigen-binding fragment of the present disclosure is capable of neutralizing infection by RSV and / or MPV. As used herein, a "neutralizing antibody" is one that can neutralize, i.e., prevent, inhibit, reduce, impede, or interfere with, the ability of a pathogen to initiate and / or perpetuate an infection in a host. The terms "neutralizing antibody" and "an antibody that neutralizes" or "antibodies that160587589.120 neutralize" are used interchangeably herein. In any of the presently disclosed embodiments, the antibody or antigen-binding fragment is capable of preventing and / or neutralizing an RSV and / or MPV infection in an in vitro model of infection, in an in vivo animal model of infection and / or in a human. 5 In certain embodiments, the antibody or antigen binding fragment is an RSV / MPV cross-binding and / or neutralizing antibody or antigen-binding fragment as set forth in Table 1, Table 2, Table 3, or Table 4, optionally excluding MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, and RSD5 antibodies set forth in Tables 1 and 2. 10 Similar naming conventions are used for the antibodies herein according the following principles, which apply to antibody and variant designations. As used herein, “MPK190” without further identification as a variant (e.g. MPK190- v1.3) refers to an antibody having a MPK190 VH (e.g., SEQ ID NO:29) and a MPK190 VL (e.g., SEQ ID NO:206), as set forth in Table 1, Table 2, Table 3, or Table 4 or CDRs 15 associated with MPK190 VH (e.g., SEQ ID NOs:202-204) and MPK190 VL (e.g., SEQ ID NOs: 207-209) as set forth in Table 1, Table 2, Table 3, or Table 4 and a rIgG1 constant region, such as a heavy chain constant region as set forth in any one of SEQ ID NOs:498-536 or a heavy chain constant region having a YTE mutation, such as any one of SEQ ID NOS:580- 582, 594-601. Such an antibody may further have a light chain constant region, such as the 20 amino acid sequence as set forth in SEQ ID NO: 95. MPK190-v1.3 is also referred to herein as "ML-190-1.3”. Further variant antibodies described in Table 1, Table 2, Table 3, or Table 4, are referred to as “ML-M-190[#]” and represent variants of the MPK190-v1.3 antibody. MPK190- v1.3 variants are described in Table 1, Table, 2, Table 3, and Table 4. “MPK190-v[#]” refers to a variant of MPK190 as set 25 forth in Table 1, Table 2, Table 3, and Table 4,, which are collectively called MPK190 “variants.” The first number or only number in a variant refers to a VH variant and a two number “x.y” variant refers to a VH.VL variant. For example, MPK190-v1.3 refers to an MPK antibody having VH.1 and VL.3. Typically, unless indicated otherwise by sequences herein, VH.1 refers to the parental VH and VL.1 refers to the parental VL. MPK190-v1.3 variants may 30 also have designations as “R-#”. RSD5 is described in Tables 1 and 2. MPE33 and MPE8 are described in Corti et al. Nature.2013 Sep 19;501(7467):439-43. doi: 10.1038 / nature12442. Epub 2013 Aug 18. MPF5, and RSD5 are described in Jones et al. PLoS Patho.15(7):e1007944 (2019); doi:10.1371 / journal.ppat.1007944.160587589.121 In certain embodiments, the antibody or antigen-binding fragment is human, humanized, or chimeric. In certain embodiments, the antibody or antigen-binding fragment is capable of binding to or neutralizing two or more of RSV-F, MPV-F D280, and MPV-F N280 with a KD or IC50 of 5 10-10or higher for each protein as indicated above or as indicated for MPK190 antibodies in the Examples. In certain embodiments, the antibody or antigen-binding fragment is capable of binding to or neutralizing DS-Cav1, or two or more of DS-Cav1, RSV-F, MPV-F D280, and MPV-F N280 with a KD or IC50 for each protein as indicated above. 10 In certain embodiments, the RSV-F comprises DS-Cav1, a stabilized trimer of the pre- fusion conformation of the RSV-F protein that comprises the amino acid mutation(s): S155C, S190F, V207L, and S290C wherein, optionally, the RSV comprises strain B18537. In certain embodiments, the antibody or antigen-binding fragment is capable of activating a human FcγRIIIa. In further embodiments, activation is as determined using a host 15 cell (optionally, a Jurkat cell) comprising: (i) the human FcγRIIIa (optionally, a F158 allele); and (ii) a NFAT expression control sequence operably linked to a sequence encoding a reporter, such as a luciferase reporter, following incubation (e.g., of 23 hours) of the antibody or antigen- binding fragment with a target cell (e.g., a Expi293 cell) transiently transfected with RSV-F and / or MPV-F. In still further embodiments, activation is as determined following an 20 incubation (optionally, for about 23 hours) of the antibody or antigen-binding fragment with the target cell transiently transfected with RSV-F and / or MPV-F. In certain embodiments, the antibody or antigen-binding fragment is capable of neutralizing infection by RSV and / or MPV. In certain embodiments, the RSV and / or the MPV is antiviral-resistant (e.g. Ribavirin-resistant). In certain embodiments, the MPV does not 25 contain the D280N mutation in its fusion glycoprotein. In certain embodiments, the MPV does contain the D280N mutation in its fusion glycoprotein. In certain embodiments, the antibody or antigen-binding fragment is capable of treating and / or preventing (i) a RSV infection and / or (ii) a MPV infection in a subject. In certain embodiments, the antibody or antigen-binding fragment is capable extending 30 survival of a subject having a RSV infection and / or a MPV infection. In certain embodiments, the antibody or antigen-binding fragment is capable of reducing viral loads in the nasal tissue, nasal homogenates, bronchoalveolar fluid (BALF), and / or lung homogenates of a subject having a RSV infection and / or a MPV infection.160587589.122 In certain embodiments, the antibody or antigen-binding fragment is capable of reducing infection-associated pulmonary pathology of a subject having a RSV infection and / or a MPV infection. In any of the above embodiments, the antibody or antigen-binding fragment may be 5 capable of treating and / or attenuating an infection by a MPV virus expressing MPV-F D280, such as MPV-F wt, and / or by a MPV virus expressing MPV-F N280. Such an antibody may be therapeutically administered to a human subject without the need to ascertain whether a MPV virus infecting the subject contains the MPV-F N280 mutation. In some embodiments, antibodies or antigen-binding fragments thereof of the present 10 disclosure may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of multiple RSV and / or MPV strains (also sometimes referred to as RSV and / or MPV types or subtypes). For example, a RSV-binding antibody or antigen-binding fragment thereof may bind to, 15 neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of both RSV A and RSV B strains. A RSV-binding antibody may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of multiple subtypes of RSV A strains. 20 A RSV-binding antibody or antigen-binding fragment thereof may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of multiple subtypes of RSV B strains. Also for example, a MPV-binding antibody or antigen-binding fragment thereof may 25 bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology, or any combinations thereof, of both MPV A and MPV B strains. A MPV-binding antibody may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection- associated pulmonary pathology or, or any combinations thereof, of multiple subtypes of MPV 30 A strains, such as MPV A1 strains, MPV A2 strains (including A2a, A2b , or both subtypes), or combinations thereof. A MPV-binding antibody or antigen-binding fragment thereof may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of multiple subtypes of MPV B strains, such as MPV B1 strains, MPV B2 strains, or160587589.123 combinations thereof. In one embodiment, an antibody or antigen-binding fragment thereof of the present disclosure may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any 5 combinations thereof, of a RSV A strain, a RSV B strain, and a MPV A strain. In another embodiment, an antibody or antigen-binding fragment thereof of the present disclosure may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of a RSV A strain, a RSV B strain, and a MPV B strain. 10 In another embodiment, an antibody or antigen-binding fragment thereof of the present disclosure may bind to, neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of a RSV A strain, a MPV A strain, and a MPV B strain. In another embodiment, an antibody or antigen-binding fragment thereof may bind to, 15 neutralize, neutralize infection by, prevent infection by, treat infection by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of a RSV B strain, a MPV A strain, and a MPV B strain. In one embodiment, an antibody or antigen-binding fragment thereof of the present disclosure may bind to, neutralize, neutralize infection by, prevent infection by, treat infection 20 by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of any combination of subcombination of the following viral strains: RSV A, RSV B, MPV A1, MPV A2 (MPV A2a, MPV A2b, or both), MPV B1, and MPV B2. In a specific embodiment an antigen or antigen-binding fragment thereof of the present disclosure may bind to, neutralize, neutralize infection by, prevent infection by, treat infection 25 by, reduce viral load of, reduce infection-associated pulmonary pathology or, or any combinations thereof, of RSV A, RSV B, MPV A1, MPV A2, MPV B1, and MPV B2. In any of the above embodiments, an antibody or antigen-binding fragment that may treat and / or attenuate (or be “capable of treating and / or attenuating” or “able to treat and / or attenuate”) an infection by both RSV A and RSV B strains may be therapeutically administered 30 to a human subject without the need to ascertain the viral subtype of a RSV virus infecting the subject. Similarly, an antibody or antigen-binding fragment that may treat and / or attenuate (or be “capable of treating and / or attenuating” or “able to treat and / or attenuate”) an infection by both MPV A and MPV B strains may be therapeutically administered to a human160587589.124 subject without the need to ascertain the viral subtype of a MPV virus infecting the subject. Additionally, an antibody or antigen-binding fragment that may treat and / or attenuate (or be “capable of treating and / or attenuating” or “able to treat and / or attenuate”) an infection by both RSV A and RSV B strains and both MPV A and MPV B strains may be therapeutically 5 administered to a human subject without the need to ascertain whether RSV or MPV is infecting the subject. In one embodiment, the antibody or antigen-binding fragment thereof of the present disclosure binds to Site III of the RSV F protein. In a more specific embodiment, such an antibody or antigen-binding fragment thereof may bind to and treat infection by both RSV and 10 MPV. In one embodiment, the antibody or antigen-binding fragment thereof of the present disclosure binds to Site Ø of RSV F protein. In a more specific embodiment, such an antibody or antigen-binding fragment thereof may bind to and treat infection by RSV. In one embodiment, the antibody or antigen-binding fragment thereof of the present 15 disclosure binds to Site IV of the RSV F protein. In a more specific embodiment, such an antibody or antigen-binding fragment thereof may bind to and treat infection by RSV. For each embodiment of the antibodies, antigen-binding fragment, and compositions above, in parallel embodiments, a combination of two or more antibodies or antigen-binding fragments thereof of the present disclosure, either as separate antibodies in a single 20 composition, or in a bispecific antibody, may have the same RSV and MPV binding, neutralizing, infection preventing and / or treating, and other recited properties. In certain embodiments, the antibody or antigen-binding fragment (e.g., comprising an IgG1 isotype) has an in vivo half-life in a mouse (e.g., a tg32 mouse) in a range from about 10 days to about 17 days, about 10 days to about 16 days, about 10 days to about 15 days, about 10 25 days to about 14 days, about 10 days to about 13 days, about 10 days to about 12 days, about 11 days to about 17 days, about 11 days to about 16 days, about 11 days to about 15 days, about 11 days to about 14 days, about 11 days to about 13 days, about 11 days to about 12 days, about 12 days to about 17 days, about 12 days to about 16 days, about 12 days to about 15 days, about 12 days to about 14 days, about 12 days to about 13 days, about 12.5 days to about 16 days, about 30 12.5 days to about 15.5 days, about 12.5 days to about 15 days, about 12.5 days to about 14.5 days, about 12.5 days to about 14 days, about 12.5 days to about 13.5 days, about 12.5 days to about 13 days, about 13 days to about 16 days, about 13 days to about 15.5 days, about 13 days to about 15 days, about 13 days to about 14.5 days about 13 days to about 14 days, about 13 days to about 13.5 days, about 13.5 days to about 16 days, about 13.5 days to about160587589.125 15.5 days, about 13.5 days to about 15 days, about 13.5 days to about 14.5 days, about 13.5 days to about 14 days, about 14 days to about 16 days, about 14 days to about 15.5 days, about 14 days to about 15 days, about 14 days to about 14.5 days, about 14.5 days to about 16 days, about 14.5 days to about 15.5 days, about 14.5 days to about 15 days, about 15 days to about 16 5 days, about 15 days to about 15.5 days, about 15.5 days to about 16 days, or of about 10, 11, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, or 17 days. In some embodiments, an antibody or antigen-binding fragment of the present disclosure may reduce weight loss in RSV-infected mice at least as well as nirsevimab when administered in a similar manner to similar mice in a similar stage of RSV infection. 10 In some embodiments, an antibody or antigen-binding fragment of the present disclosure may increase survival of RSV-infected mice at least as well as nirsevimab, or an antibody having the same VH and VL as niservimab, when administered in a similar manner to similar mice in a similar stage of RSV infection. Terms understood by those in the art of antibody technology are each given the 15 meaning acquired in the art, unless expressly defined differently herein. For example, the term "antibody" refers to an intact antibody comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as any antigen-binding portion or fragment of an intact antibody that has or retains the ability to bind to the antigen target molecule recognized by the intact antibody, such as an scFv, Fab, or Fab'2 fragment. Thus, the 20 term "antibody" herein is used in the broadest sense and includes polyclonal and monoclonal antibodies, including intact antibodies and functional (antigen-binding) antibody fragments, including fragment antigen binding (Fab) fragments, F(ab')2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rIgG) fragments, single chain antibody fragments, including single chain variable fragments (scFv), and single domain antibodies (e.g., sdAb, sdFv, 25 nanobody) fragments. The term encompasses genetically engineered and / or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecific, e.g., bispecific antibodies, diabodies, triabodies, tetrabodies, tandem di-scFv, and tandem tri-scFv. Unless otherwise stated, the term "antibody" should be understood to encompass functional antibody 30 fragments. The term also encompasses intact or full-length antibodies, including antibodies of any class or sub-class, including IgG and sub-classes thereof (IgG1, IgG2, IgG3, IgG4), IgM, IgE, IgA, and IgD. An antibody or antigen-binding fragment, may be of any allotype or combination of allotypes. “Allotype” refers to the allelic variation found among the IgG160587589.126 subclasses. For example, an allotype may comprise G1m1 (or G1m(a)), G1m2 (or G1m(x)), G1m3 (or G1m(f)), G1m17 (or Gm(z))m), G1m27, and / or G1m28 (G1m27 and G1m28 have been described as “alloallotypes”). The G1m3 and G1m17 allotypes are located at the same position in the CH1 domain 5 (position 214 according to EU numbering). G1m3 comprises R214 (EU), while G1m17 comprises K214 (EU). The G1m1 allotype is located in the CH3 domain (at positions 356 and 358 (EU)) and refers to the replacements E356D and M358L. The G1m2 allotype refers to a replacement of the alanine in position 431 (EU) by a glycine. G1m allotypes, alloallotypes, and features thereof are known in the art and described at, for example, 10 www.imgt.org / IMGTrepertoire / Proteins / allotypes / human / IGH / IGHC / G1m_allotypes.html and Lefranc, M.-P. and Lefranc, G. Human Gm, Km and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism In: B. Tait, F. Christiansen (Eds.), Immunogenetics, chap.34, Humana Press, Springer, New York, USA. Methods Mol. Biol.2012; 882, 635-680. PMID: 22665258, LIGM: 406, the contents and allotypes and 15 allotype information of which are incorporated herein by reference. The G1m1 allotype may be combined, for example, with the G1m3, G1m17, G1m27, G1m2, and / or G1m28 allotype. In some embodiments, an allotype is G1m3 with no G1m1 (G1m3,-1). In some embodiments, an allotype is G1m17,1 allotype. In some embodiments, an allotype is G1m3,1. In some embodiments, an allotype is G1m17 with no G1m1 (G1m17,-1). 20 Optionally, these allotypes may be combined (or not combined) with the G1m2, G1m27 or G1m28 allotype. For example, an allotype may be G1m17,1,2. In some embodiments, an antibody or antigen-binding fragment of the present disclosure comprises a G1m3 allotype or a G1m3,1 allotype. In some embodiments, an antibody or antigen-binding fragment of the present disclosure comprises a G1m3 allotype and 25 comprises M428L and N434S or M428L and N434A mutations or any other mutation(s) that enhance binding to a human FcRn, such as those described herein. In some embodiments, an antibody or antigen-binding fragment of the present disclosure comprises a G1m3,1 allotype and comprises M428L and N434S or M428L and N434A mutations or any other mutation(s) that enhance binding to a human FcRn, such as those described herein. In some embodiments, 30 an antibody or antigen-binding fragment of the present disclosure comprises a G1m17, 1 allotype. In some embodiments, an antibody or antigen-binding fragment of the present disclosure comprises a G1m17, 1 allotype and comprises M428L and N434S or M428L and N434A mutations or any other mutation(s) that enhance binding to a human FcRn, as described further herein. In some embodiments, an antibody or antigen-binding fragment of160587589.127 the present disclosure comprises a G1m17,1 allotype and comprises M252Y / S254T / T256E mutations, and optionally M428L / N434S mutations. In some embodiments, an antibody or antigen-binding fragment of the present disclosure comprises a G1m3 allotype and comprises M252Y / S254T / T256E, and optionally M428L / N434S mutations. In some embodiments, an 5 antibody or antigen-binding fragment of the present disclosure comprises a G1m3,1 allotype and comprises M252Y / S254T / T256E mutations, and optionally M428L / N434S mutations. Examples of G1m17,1, G1m3, and G1m3,1 allotype sequences are provided in Table 1. The terms "VL" or "VL" and "VH" or "VH" refer to the variable binding region from an antibody light chain and an antibody heavy chain, respectively. In certain embodiments, a 10 VL is a kappa (κ) class (also "VK" herein). In certain embodiments, a VL is a lambda (λ) class. The variable binding regions comprise discrete, well-defined sub-regions known as "complementarity determining regions" (CDRs) and "framework regions" (FRs). The terms "complementarity determining region," and "CDR," are synonymous with "hypervariable region" or "HVR," and refer to sequences of amino acids within antibody variable regions, 15 which, in general, together confer the antigen specificity and / or binding affinity of the antibody, wherein consecutive CDRs (i.e., CDR1 and CDR2, CDR2 and CDR3) are separated from one another in primary structure by a framework region. There are three CDRs in each variable region (HCDR1, HCDR2, HCDR3; LCDR1, LCDR2, LCDR3; also referred to as CDRHs and CDRLs, respectively). In certain embodiments, an antibody VH comprises four FRs and three 20 CDRs as follows: FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4; and an antibody VL comprises four FRs and three CDRs as follows: FR1-LCDR1-FR2-LCDR2-FR3-LCDR3-FR4. In general, the VH and the VL together form the antigen-binding site through their respective CDRs. In certain embodiments, one or more CDRs do not contact antigen and / or do not contribute energetically to antigen binding. 25 As used herein, a "variant" of a CDR refers to a functional variant of a CDR sequence having up to 1-3 amino acid substitutions (e.g., conservative or non-conservative substitutions), deletions, or combinations thereof. Numbering of CDR and framework regions may be according to any known method or scheme, such as the Kabat, Chothia, EU, IMGT, Contact, North, Martin, AbM, and AHo 30 numbering schemes (see, e.g., Kabat et al., "Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, Public Health Service National Institutes of Health, 1991, 5th ed.; Chothia and Lesk, J. Mol. Biol.196:901-917 (1987)); Lefranc et al., Dev. Comp. Immunol.27:55, 2003; Honegger and Plückthun, J. Mol. Bio.309:657-670 (2001); North et al. J Mol Biol. (2011) 406:228–56; doi:10.1016 / j.jmb.2010.10.030; Abhinandan and160587589.128 Martin, Mol Immunol. (2008) 45:3832–9.10.1016 / j.molimm.2008.05.022). The antibody and CDR numbering systems of these references are incorporated herein by reference. Equivalent residue positions can be annotated and for different molecules to be compared using Antigen receptor Numbering And Receptor Classification (ANARCI) software tool (2016, 5 Bioinformatics 15:298-300). Accordingly, identification of CDRs of an exemplary variable domain (VH or VL) sequence as provided herein according to one numbering scheme is not exclusive of an antibody comprising CDRs of the same variable domain as determined using a different numbering scheme. In certain embodiments, an antibody or antigen-binding fragment that binds RSV-F 10 and / or MPV-F is provided that can comprise heavy chain variable domain (VH) comprising the complementarity determining region (CDR)H1, CDRH2, and CDRH3 amino acid sequences of the VH or Fd amino acid sequence set forth in any one of SEQ ID NOs.:1-57 and 97 and a light chain variable domain (VL) comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL or light chain (LC) amino acid sequence set forth in any one of SEQ ID 15 NOs.:58-91, 93 and 94, as determined using any known CDR numbering method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, CDRs are according to the IMGT numbering method. In certain embodiments, CDRs are according to the antibody numbering method developed by the 20 Chemical Computing Group (CCG); e.g., using Molecular Operating Environment (MOE) software (www.chemcomp.com). In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH or Fd amino acid sequence set forth in any one of SEQ ID NOs.: SEQ ID 25 NOS:1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL or light chain (LC) amino acid sequence set forth in any one of SEQ ID NOs: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 30 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, as determined using any known CDR numbering method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, CDRs are according to the IMGT numbering method. In certain embodiments, CDRs are160587589.129 according to the antibody numbering method developed by the Chemical Computing Group (CCG); e.g., using Molecular Operating Environment (MOE) software (www.chemcomp.com). In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid 5 sequences of the VH amino acid sequence set forth in SEQ ID NO:1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:94; (b) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 2, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID 10 NO: 94; (c) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 3, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (d) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 4, and a VL comprising the CDRL1, CDRL2, and 15 CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (e) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 5, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (f) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid 20 sequence set forth in SEQ ID NO: 6, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (g) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 7, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (h) a VH 25 comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 8, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (i) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 10, and a VL comprising the CDRL1, CDRL2, and CDRL3 30 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (j) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 11, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (k) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH160587589.130 amino acid sequence set forth in SEQ ID NO: 12, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (l) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 13, and a VL comprising the CDRL1, CDRL2, and 5 CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (m) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 14, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (n) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid 10 sequence set forth in SEQ ID NO: 15, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (o) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 15, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (p) a VH 15 comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 16, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (q) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 17, and a VL comprising the CDRL1, CDRL2, and CDRL3 20 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (r) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 18, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (s) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid 25 sequence set forth in SEQ ID NO: 19, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (t) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO:20, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (u) a VH 30 comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 21, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (v) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 22, and a VL comprising the CDRL1, CDRL2,160587589.131 and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (w) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 23, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; 5 (x) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 24, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (y) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 25, and a VL comprising the CDRL1, CDRL2, and CDRL3 10 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (z) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 26, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (aa) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid 15 sequence set forth in SEQ ID NO: 27, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (bb) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 28, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (cc) a VH 20 comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 29, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (dd) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 30, and a VL comprising the CDRL1, CDRL2, and CDRL3 25 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (ee) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 31, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (ff) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid 30 sequence set forth in SEQ ID NO: 32, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (gg) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 33, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94;160587589.132 (hh) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 34, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (ii) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino 5 acid sequence set forth in SEQ ID NO: 35, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (jj) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 36, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (kk) a VH 10 comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 37, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (ll) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 38, and a VL comprising the CDRL1, CDRL2, and CDRL3 15 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (mm) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 39, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (nn) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid 20 sequence set forth in SEQ ID NO: 40, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (oo) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 41, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (pp) a VH 25 comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 42, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (qq) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 43, and a VL comprising the CDRL1, CDRL2, and CDRL3 30 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (rr) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 44, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (ss) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH160587589.133 amino acid sequence set forth in SEQ ID NO: 45, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (tt) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 46, and a VL comprising the CDRL1, CDRL2, and 5 CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (uu) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 47, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (vv) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino 10 acid sequence set forth in SEQ ID NO: 48, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (ww) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 49, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; 15 (xx) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 50, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (yy) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 51, and a VL comprising the CDRL1, CDRL2, 20 and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (zz) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 52, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (aaa) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH 25 amino acid sequence set forth in SEQ ID NO: 53, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (bbb) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 54, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; 30 (ccc) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 55, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (ddd) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 56, and a VL comprising the160587589.134 CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (eee) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 57, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in 5 SEQ ID NO: 94; (fff) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 59; (ggg) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the 10 CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 61; (hhh) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 62; (iii) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid 15 sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 63; (jjj) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in 20 SEQ ID NO: 64; (kkk) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 65; (lll) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the 25 CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 66; (mmm) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 67; (nnn) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid 30 sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 68; (ooo) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid160587589.135 sequence set forth in SEQ ID NO: 69; (ppp) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 70; (qqq) a VH comprising the CDRH1, CDHR2, and 5 CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 71; (rrr) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid 10 sequence set forth in SEQ ID NO: 72; (sss) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 73; (ttt) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL 15 comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 74; (uuu) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 76; (vvv) a VH comprising the CDRH1, CDHR2, and 20 CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 77; (www) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid 25 sequence set forth in SEQ ID NO: 79; (xxx) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 81; (yyy) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a 30 VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 82; (zzz) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 83; (aaaa) a VH comprising the CDRH1,160587589.136 CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 84; (bbbb) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ 5 ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 86; (cccc) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 87; (dddd) a VH comprising the CDRH1, 10 CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 88; (eeee) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the 15 VL amino acid sequence set forth in SEQ ID NO: 89; (ffff) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 91; (gggg) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ 20 ID NO: 201, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 206; (hhhh) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 206; (iiii) a VH comprising 25 the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 214; (jjjj) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 133, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid 30 sequences of the VL amino acid sequence set forth in SEQ ID NO: 165; (kkkk) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 115, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (llll) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH160587589.137 amino acid sequence set forth in SEQ ID NO: 115, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 165; (mmmm) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 111, and a VL comprising the CDRL1, CDRL2, 5 and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 165; (nnnn) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 133, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 94; (oooo) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH 10 amino acid sequence set forth in SEQ ID NO: 240, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 241; (pppp) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 242, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 243; 15 (qqqq) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 244, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 245; (rrrr) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 246, and a VL comprising the CDRL1, CDRL2, 20 and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 245; (ssss) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 47, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 245; (tttt) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH 25 amino acid sequence set forth in SEQ ID NO: 248, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 243; (uuuu) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 249, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 250; 30 (vvvv) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 251, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 252; (wwww) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 253, and a VL comprising the160587589.138 CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 254; (xxxx) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 255, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set 5 forth in SEQ ID NO: 256; (yyyy) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 257, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 258; or (zzzz) a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 259, 10 and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 260, wherein the CDRs are determined using any known CDR numbering method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, CDRs are according to the IMGT 15 numbering method. In certain embodiments, CDRs are according to the antibody numbering method developed by the Chemical Computing Group (CCG); e.g., using Molecular Operating Environment (MOE) software (www.chemcomp.com). In some embodiments, the antibody or antigen-binding fragment thereof does not comprise all of the CDRH1-CDRH3 and CDRL1-CDRL3 amino acid sequences of MPK190, 20 MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176- v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5 antibodies. Sequences for MPK190, MPK190- v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, and RSD5 antibodies are set forth in Tables 1 and 2. CDRH1- CDRH3 and CDRL1-CDRL3 of MPK190 and MPK190-v1.1 antibodies are set forth SEQ ID 25 NOS:202-204 and 207-209, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1- CDRL3 of MPK190-v1.3 antibody are set forth in SEQ ID NOS:202-204, 215, 216, and 209, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1-CDRL3 of MPK65-v2-1.2 antibody are set forth in SEQ ID NOS:539-541 and 544-546, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1-CDRL3 of MPK65-v2-v3.1 antibody are set forth in SEQ ID 30 NOS: 549, 550, 541, 544, 545, and 553, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1-CDRL3 of MPK176-v1.3 antibody are set forth in SEQ ID NOS: 556-558 and 561- 563, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1-CDRL3 of MPK176-v4.3 antibody are set forth in SEQ ID NOS:556, 566, 558, and 561-563, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1-CDRL3 of MPK201-v1.2 antibody are160587589.139 set forth in SEQ ID NOS: 539, 569, 570, 544, 545, and 573, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1-CDRL3 of MPK201-v4.1 antibody are set forth in SEQ ID NOS:549, 569, 570, 544, 545, and 578, respectively (IMGT numbering). CDRH1-CDRH3 and CDRL1-CDRL3 of RSD5 antibody are set forth in SEQ ID NOS:228-230 and 233-235, 5 respectively (IMGT numbering). In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO:251, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set 10 forth in SEQ ID NO:252, as determined using any known CDR method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid 15 sequences of the VH amino acid sequence set forth in SEQ ID NO:240, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:241, as determined using any known CDR method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. 20 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO:247, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:245, as determined using any known CDR method, including the Kabat, 25 Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and Aho numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 242, and a VL comprising 30 the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 243, as determined using any known CDR method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods.160587589.140 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 244, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set 5 forth in SEQ ID NO:245, as determined using any known CDR method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid 10 sequences of the VH amino acid sequence set forth in SEQ ID NO: 255, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:256, as determined using any known CDR method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. 15 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 253, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:254, as determined using any known CDR method, including the Kabat, 20 Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 257, and a VL comprising 25 the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:258, as determined using any known CDR method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering methods, including as determined by a combination of any two or more of these numbering methods. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F 30 and / or MPV-F comprises a VH comprising the CDRH1, CDHR2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 259, and a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:260, as determined using any known CDR method, including the Kabat, Chothia, EU, IMGT, Martin (Enhanced Chothia), Contact, and AHo numbering160587589.141 methods, including as determined by a combination of any two or more of these numbering methods. More specifically, the VH and VL for an antibody or antigen-binding fragment that 5 binds RSV-F and / or MPV-F comprise or consist of any VH and any VL identified for the MPK190-v1.3 variant antibodies (but not both as identified for the parental MPK190-v1.3 antibody) in Table 1, Table 2, Table 3, or Table 4. In some embodiments, the VH and VL are both from the same antibody identified in Table 1, Table 2, Table 3, or Table 4. However, in other embodiments, the VH may be from a first antibody identified in Table 1, Table 2, Table 10 3, or Table 4while VL may be from a second, different antibody identified in Table 1, Table 2, Table 3, or Table 4. Cross-binding and / or cross-neutralizing antibodies and antigen-binding fragments of the present disclosure may also be used to bind RSV-F alone, or to bind MPV-F alone; their utility is not limited to a context where binding and / or neutralization of both RSV and MPV 15 targets occurs. Framework regions can be identified according to a numbering scheme (e.g., IMGT, Kabat, Chothia, North, EU, Martin (Enhanced Chothia), Contact, AbM, CCG, or AHo, or a combination of two or more of these). The CDRs may be identified within a variable domain or within a heavy or light chain according to a numbering scheme or a combination of numbering 20 schemes, and, preferably, the FRs may be identified using the same numbering scheme or combination of numbering schemes. In certain embodiments, an antibody or antigen-binding fragment comprises a VH comprising a FR1, a FR2, a FR3, and / or a FR4 (or a variant of the FR1, FR2, FR3, and / or FR4 comprising one, two, three, four, or five amino acid substitutions, insertions, and / or deletions) 25 of the VH amino acid sequence set forth in any one of SEQ ID NOs.:1-57 and 97, and a VL comprising a FR1, a FR2, a FR3, and / or a FR4 (or a variant of the FR1, FR2, FR3, and / or FR4 comprising one, two, three, four, or five amino acid substitutions, insertions, and / or deletions) of the VL amino acid sequence set forth in any one of SEQ ID NOs.:58-91, 93 and 94. In some embodiments, the FRs are defined in accordance with the IMGT, Kabat, Chothia, North, EU, 30 Martin (Enhanced Chothia), Contact, AbM, CCG, or AHo numbering system, or in accordance with any combination thereof. In some embodiments, an antibody or antigen-binding fragment comprises: (i) a heavy chain variable domain (VH) comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.:1-57 and 97; and (ii) a light chain variable domain (VL) comprising, consisting essentially of, or160587589.142 consisting of the amino acid sequence set forth in any one of SEQ ID NOs.:58-91, 93 and 94. In certain embodiments, an antibody or antigen-binding fragment comprises a VH comprising a FR1, a FR2, a FR3, and / or a FR4 (or a variant of the FR1, FR2, FR3, and / or FR4 comprising one, two, three, four, or five amino acid substitutions, insertions, and / or deletions) 5 of the VH amino acid sequence set forth in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, and a VL comprising a FR1, a FR2, a FR3, and / or a FR4 (or a variant of the FR1, FR2, FR3, and / or FR4 comprising one, two, three, four, or five amino acid substitutions, insertions, and / or 10 deletions) of the VL amino acid sequence set forth in any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260. In some embodiments, the FRs are defined in accordance with the IMGT, Kabat, Chothia, North, EU, Martin (Enhanced Chothia), Contact, AbM, CCG, or AHo numbering system, or in accordance with any combination 15 thereof. In certain embodiments, an antibody or antigen-binding fragment comprises: (i) a heavy chain variable domain (VH) comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 20 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259; and (ii) a light chain variable domain (VL) comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260. 25 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:94; (b) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 2, 30 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (c) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 3, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (d) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.143 ID NO: 4, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (e) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 5, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 5 (f) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 6, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (g) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 7, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 10 (h) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 8, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (i) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 10, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 15 (j) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 11, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (k) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 12, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 20 (l) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 13, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (m) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 14, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 25 (n) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 15, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (o) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 15, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 30 (p) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 16, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (q) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 17, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.144 ID NO: 94; (r) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 18, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (s) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 19, 5 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (t) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:20, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (u) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 21, 10 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (v) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 22, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (w) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 23, 15 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (x) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 24, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (y) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 25, 20 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (z) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 26, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (aa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 27, 25 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (bb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 28, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (cc) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 29, 30 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (dd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 30, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ee) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.145 ID NO: 31, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ff) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 32, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 5 (gg) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 33, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (hh) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 34, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 10 (ii) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 35, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (jj) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 36, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 15 (kk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 37, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 38, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 20 (mm) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 39, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (nn) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 40, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 25 (oo) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 41, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (pp) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 42, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 30 (qq) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 43, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (rr) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 44, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.146 ID NO: 94; (ss) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 45, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (tt) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 46, 5 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (uu) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 47, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (vv) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 48, 10 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ww) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 49, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (xx) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 50, 15 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (yy) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 51, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (zz) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 52, 20 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (aaa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 53, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (bbb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ 25 ID NO: 54, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ccc) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 55, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ddd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 30 forth in SEQ ID NO: 56, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (eee) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 57, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (fff) a VH comprising, consisting essentially of, or consisting of the amino acid160587589.147 sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 59; (ggg) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 5 forth in SEQ ID NO: 61; (hhh) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 62; (iii) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 10 forth in SEQ ID NO: 63; (jjj) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 64; (kkk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 15 forth in SEQ ID NO: 65; (lll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 66; (mmm) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 20 forth in SEQ ID NO: 67; (nnn) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 68; (ooo) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 25 forth in SEQ ID NO: 69; (ppp) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 70; (qqq) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 30 forth in SEQ ID NO: 71; (rrr) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 72; (sss) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid160587589.148 sequence set forth in SEQ ID NO: 73; (ttt) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 74; (uuu) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 5 forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 76; (vvv) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 77; (www) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 10 forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 79; (xxx) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 81; (yyy) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 15 forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 82; (zzz) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 83; (aaaa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 20 forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 84; (bbbb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 86; (cccc) a VH comprising, consisting essentially of, or consisting of the amino acid 25 sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 87; (dddd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 88; (eeee) a VH comprising, consisting essentially of, or consisting of the 30 amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 89; (ffff) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 91; (gggg) a VH comprising, consisting essentially of, or160587589.149 consisting of the amino acid sequence set forth in SEQ ID NO: 201, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 206; (hhhh) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising, consisting essentially of, or consisting of the 5 amino acid sequence set forth in SEQ ID NO: 206; (iiii) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 214; (jjjj) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 133, and a VL comprising, consisting essentially of, or 10 consisting of the amino acid sequence set forth in SEQ ID NO: 165; (kkkk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 115, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (llll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 115, and a VL comprising, consisting essentially 15 of, or consisting of the amino acid sequence set forth in SEQ ID NO: 165; (mmmm) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 111, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 165; (nnnn) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 133, and a VL comprising, 20 consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (oooo) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 240, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 241; (pppp) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 242, and a VL 25 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 243; (qqqq) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 244, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 245; (rrrr) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 246, 30 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 245; (ssss) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 247, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 245; (tttt) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set160587589.150 forth in SEQ ID NO: 248, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 243; (uuuu) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 249, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ 5 ID NO: 250; (vvvv) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 251, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 252; (wwww) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 253, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 10 forth in SEQ ID NO: 254; (xxxx) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 255, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 256; (yyyy) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 257, and a VL comprising, consisting essentially of, or consisting of the amino 15 acid sequence set forth in SEQ ID NO: 258; or (zzzz) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 259, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 260. In some embodiments, a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 201, and a VL comprising, consisting 20 essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 206; or a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 206; or a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising, 25 consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 214 are excluded from said antibody or antigen-binding fragment thereof. In some embodiments, a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:94; a VH comprising, consisting essentially of, or consisting 30 of the amino acid sequence set forth in SEQ ID NO: 201, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 206; a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 206; and a VH comprising, consisting essentially160587589.151 of, or consisting of the amino acid sequence set forth in SEQ ID NO: 211, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 214 are excluded from the antibody or antigen-binding fragment thereof of the present disclosure. 5 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:251, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:252. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F 10 and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:240, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:241. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the 15 amino acid sequence set forth in SEQ ID NO:247, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:245. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:242, and (b) a VL comprising, consisting 20 essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:243. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:244, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:245. 25 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:255, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:256. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F 30 and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:253, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:254. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or160587589.152 consisting of the amino acid sequence set forth in SEQ ID NO:257, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:258. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the 5 amino acid sequence set forth in SEQ ID NO:259, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:260. The term "CL" refers to an "immunoglobulin light chain constant region" or a "light chain constant region," i.e., a constant region from an antibody light chain. The term "CH" refers to an "immunoglobulin heavy chain constant region" or a "heavy chain constant region," 10 which is further divisible, depending on the antibody isotype, into CH1, CH2, and CH3 (IgA, IgD, IgG), or CH1, CH2, CH3, and CH4 domains (IgE, IgM). The Fc region of an antibody heavy chain is described further herein. In any of the presently disclosed embodiments, an antibody or antigen-binding fragment of the present disclosure comprises any one or more of CL, a CH1, a CH2, and a CH3. 15 A "Fab" (fragment antigen binding) is the part of an antibody that binds to antigens and includes the variable region and CH1 of the heavy chain linked to the light chain via an inter- chain disulfide bond. Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')2 fragment that roughly corresponds to two disulfide linked Fab fragments having divalent 20 antigen-binding activity and is still capable of cross-linking antigen. Both the Fab and F(ab’)2 are examples of "antigen-binding fragments." Fab' fragments differ from Fab fragments by having additional few residues at the carboxy terminus of the CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')2 antibody 25 fragments originally were produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known. Fab fragments may be joined, e.g., by a peptide linker, to form a single chain Fab, also referred to herein as "scFab." In these embodiments, an inter-chain disulfide bond that is present in a native Fab may not be present, and the linker serves in full or in part to link or 30 connect the Fab fragments in a single polypeptide chain. A heavy chain-derived Fab fragment (e.g., comprising, consisting of, or consisting essentially of VH + CH1, or "Fd") and a light chain-derived Fab fragment (e.g., comprising, consisting of, or consisting essentially of VL + CL) may be linked in any arrangement to form a scFab. For example, a scFab may be arranged, in N-terminal to C-terminal direction, according to (heavy chain Fab fragment –160587589.153 linker – light chain Fab fragment) or (light chain Fab fragment – linker – heavy chain Fab fragment). Peptide linkers and exemplary linker sequences for use in scFabs are discussed in further detail herein. "Fv" is a small antibody fragment that contains a complete antigen-recognition and 5 antigen-binding site. This fragment generally consists of a dimer of one heavy- and one light- chain variable region domain in tight, non-covalent association. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although typically at a lower affinity than the entire binding site. 10 "Single-chain Fv" also abbreviated as "sFv" or "scFv", are antibody fragments that comprise the VHand VLantibody domains connected into a single polypeptide chain. In some embodiments, the scFv polypeptide comprises a polypeptide linker disposed between and linking the VHand VLdomains that enables the scFv to retain or form the desired structure for antigen binding. Such a peptide linker can be incorporated into a fusion polypeptide using 15 standard techniques well known in the art. For a review of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol.113, Rosenburg and Moore eds., Springer- Verlag, New York, pp.269-315 (1994); Borrebaeck 1995, infra. In certain embodiments, the antibody or antigen-binding fragment comprises a scFv comprising a VH domain, a VL domain, and a peptide linker linking the VH domain to the VL domain. In particular embodiments, a 20 scFv comprises a VH domain linked to a VL domain by a peptide linker, which can be in a VH- linker VL orientation or in a VL-linker VH orientation. Any scFv of the present disclosure may be engineered so that the C-terminal end of the VL domain is linked by a short peptide sequence to the N-terminal end of the VH domain, or vice versa (i.e., (N)VL(C)-linker-(N)VH(C) or (N)VH(C)-linker-(N)VL(C). Alternatively, in some embodiments, a linker may be linked to an 25 N-terminal portion or end of the VH domain, the VL domain, or both. Peptide linker sequences may be chosen, for example, based on: (1) their ability to adopt a flexible extended conformation; (2) their inability or lack of ability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides and / or on a target molecule; and / or (3) the lack or relative lack of hydrophobic or charged residues that 30 might react with the polypeptides and / or target molecule. Other considerations regarding linker design (e.g., length) can include the conformation or range of conformations in which the VH and VL can form a functional antigen-binding site. In certain embodiments, peptide linker sequences contain, for example, Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala, may also be included in a linker sequence. Other amino acid160587589.154 sequences which may be usefully employed as linker include those disclosed in Maratea et al., Gene 40:3946 (1985); Murphy et al., Proc. Natl. Acad. Sci. USA 83:82588262 (1986); U.S. Pat. No.4,935,233, and U.S. Pat. No.4,751,180. Other illustrative and non-limiting examples of linkers may include, for example, Glu-Gly-Lys-Ser-Ser-Gly-Ser-Gly-Ser-Glu-Ser-Lys-Val- 5 Asp (Chaudhary et al., Proc. Natl. Acad. Sci. USA 87:1066-1070 (1990)) and Lys-Glu-Ser-Gly- Ser-Val-Ser-Ser-Glu-Gln-Leu-Ala-Gln-Phe-Arg-Ser-Leu-Asp (Bird et al., Science 242:423-426 (1988)) and the pentamer Gly-Gly-Gly-Gly-Ser when present in a single iteration or repeated 1 to 5 or more times, or more. Any suitable linker may be used, and in general can be about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 1523, 24, 25, 26, 27, 28, 29, 30, 10 40, 50, 60, 70, 80, 90, 100 amino acids in length, or less than about 200 amino acids in length, and will preferably comprise a flexible structure (can provide flexibility and room for conformational movement between two regions, domains, motifs, fragments, or modules connected by the linker), and will preferably be biologically inert and / or have a low risk of immunogenicity in a human. 15 scFvs can be constructed using any combination of the VH and VL sequences or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein. In some embodiments, linker sequences are not required; for example, when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to 20 separate the functional domains and prevent steric interference. During antibody development, DNA in the germline variable (V), joining (J), and diversity (D) gene loci may be rearranged and insertions and / or deletions of nucleotides in the coding sequence may occur. Somatic mutations may be encoded by the resultant sequence, and can be identified by reference to a corresponding known germline sequence. In some contexts, 25 somatic mutations that are not critical to a desired property of the antibody (e.g., binding to a RSV and / or MPV fusion glycoprotein antigen), or that confer an undesirable property upon the antibody (e.g., an increased risk of immunogenicity in a subject administered the antibody), or both, may be replaced by the corresponding germline-encoded amino acid, or by a different amino acid, so that a desirable property of the antibody is improved or maintained and the 30 undesirable property of the antibody is reduced or abrogated. Thus, in some embodiments, the antibody or antigen-binding fragment of the present disclosure comprises at least one more germline-encoded amino acid in a variable region as compared to a parent antibody or antigen- binding fragment, provided that the parent antibody or antigen binding fragment comprises one or more somatic mutations. Variable region, CDR, constant region, heavy chain,160587589.155 and light chain amino acid sequences of exemplary anti-RSV-F, anti-MPV-F, and anti-RSV-F and / or MPV-F antibodies of the present disclosure are provided in Table 1. In certain embodiments, an antibody or antigen-binding fragment comprises an amino acid modification (e.g., a substitution mutation) to remove an undesired risk of oxidation, 5 deamidation, and / or isomerization. Also provided herein are variant antibodies that comprise one or more amino acid alterations in a variable region (e.g., VH, VL, framework or CDR) as compared to a presently disclosed ("parent") antibody, wherein the variant antibody is capable of binding to a RSV and / or MPV fusion glycoprotein. 10 In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in any one of SEQ ID NOs.:1-57 and 97, wherein sequence 15 variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in any one of SEQ ID NOs.:58-91, 93 and 94, wherein 20 sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and (i) the VH comprises or consists of an amino acid sequence having at least 80% 25 (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, wherein sequence variation is optionally limited to one or more framework regions and / or sequence 30 variation comprises one or more substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86- 89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189,160587589.156 241, 243, 245, 250, 252, 254, 256, 258, and 260, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F 5 and (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 251, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more 10 substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 252, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more 15 substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to 20 the amino acid sequence set forth in SEQ ID NO: 240, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to 25 the amino acid sequence set forth in SEQ ID NO: 241, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and 30 (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 247 wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or160587589.157 (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 245, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more 5 substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to 10 the amino acid sequence set forth in SEQ ID NO: 242, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to 15 the amino acid sequence set forth in SEQ ID NO: 243, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and 20 (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 244, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or 25 (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 245, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. 30 In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 255, wherein sequence variation160587589.158 is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to 5 the amino acid sequence set forth in SEQ ID NO: 256, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and 10 (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 253, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or 15 (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 254, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. 20 In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 257, wherein sequence variation is optionally 25 limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 258, wherein sequence variation is optionally 30 limited to one or more framework regions and / or sequence variation comprises one or more substitution to a germline-encoded amino acid. In certain embodiments, the antibody is capable of binding to RSV-F and / or MPV-F and160587589.159 (i) the VH comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 259, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more 5 substitution to a germline-encoded amino acid; and / or (ii) the VL comprises or consists of an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in SEQ ID NO: 260, wherein sequence variation is optionally limited to one or more framework regions and / or sequence variation comprises one or more 10 substitution to a germline-encoded amino acid. In certain embodiments, an antibody or antigen-binding fragment of the present disclosure is monospecific (e.g., binds to a single epitope) or is multispecific (e.g., binds to multiple epitopes and / or target molecules). Antibodies and antigen binding fragments may be constructed in various formats. Exemplary antibody formats disclosed in Spiess et al., Mol. 15 Immunol.67(2):95 (2015), and in Brinkmann and Kontermann, mAbs 9(2):282-212 (2017), which formats and methods of making the same are incorporated herein by reference and include, for example, Bispecific T cell Engagers (BiTEs), DARTs, Knobs-Into-Holes (KIH) assemblies, scFv-CH3-KIH assemblies, KIH Common Light-Chain antibodies, TandAbs, Triple Bodies, TriBi Minibodies, Fab-scFv, scFv-CH-CL-scFv, F(ab')2-scFv2, tetravalent HCabs, 20 Intrabodies, CrossMabs, Dual Action Fabs (DAFs) (two-in-one or four-in-one), DutaMabs, DT- IgG, Charge Pairs, Fab-arm Exchange, SEEDbodies, Triomabs, LUZ-Y assemblies, Fcabs, κλ- bodies, orthogonal Fabs, DVD-Igs (e.g., US Patent No.8,258,268, which formats are incorporated herein by reference in their entirety), IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv- 25 IgG, IgG-2scFv, scFv4-Ig, Zybody, and DVI-IgG (four-in-one), as well as so-called FIT-Ig (e.g., PCT Publication No. WO 2015 / 103072, which formats are incorporated herein by reference in their entirety), so-called WuxiBody formats (e.g., PCT Publication No. WO 2019 / 057122, which formats are incorporated herein by reference in their entirety), and so- called In-Elbow-Insert Ig formats (IEI-Ig; e.g., PCT Publication Nos. WO 2019 / 024979 and 30 WO 2019 / 025391, which formats are incorporated herein by reference in their entirety). In certain embodiments, the antibody or antigen-binding fragment comprises two or more of VH domains, two or more VL domains, or both (i.e., two or more VH domains and two or more VL domains). In particular embodiments, an antigen-binding fragment comprises the format (N-terminal to C-terminal direction) VH-linker VL-linker VH-linker VL,160587589.160 wherein the two VH sequences can be the same or different and the two VL sequences can be the same or different. Such linked scFvs can include any combination of VH and VL domains arranged to bind to a given target, and in formats comprising two or more VH and / or two or more VL, one, two, or more different epitopes or antigens may be bound. It will be appreciated 5 that formats incorporating multiple antigen-binding domains may include VH and / or VL sequences in any combination or orientation. For example, the antigen-binding fragment can comprise the format VL-linker VH-linker VL-linker VH, VH-linker VL-linker VL-linker VH, or VL-linker VH-linker VH-linker VL. In embodiments including two VH domains and / or two VL domains, at least one VH 10 domain or VL domains or at least one or at least two CDRs therein are according to the sequences set forth for variants of MPK190-v1.3 in Table 1, Table 2, Table 3, or Table 4, optionally wherein parental MPK190, MPK190-v1.1, and MPK190-v1.3 antibodies or antigen- binding fragments thereof are excluded. In such embodiments, at least one VH or VL or at least one or at least two CDRs may also be according to the sequences set forth for variants of 15 MPK190-v1.3 in Table 1, Table 2, Table 3, and Table 4 and, optionally, for anti-RSV antibodies, according to the combinations set forth in Table 1, Table 2, Table 3 or Table 4. Monospecific or multispecific antibodies or antigen-binding fragments of the present disclosure constructed comprise any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences 20 disclosed herein in: any one of SEQ ID NOs.: 1-57 and 97 or any one of SEQ ID NOs.:58-91, 93 and 94; or any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, or any one of SEQ ID NOs: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 25 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260. A bispecific or multispecific antibody or antigen-binding fragment may, in some embodiments, comprise one, two, or more antigen-binding domains (e.g., a VH and a VL) of the instant disclosure, at least one VH or VL or at least one or at least two CDRs of which may also be according toany one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 30 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, or any one of SEQ ID NOs: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, according to any numbering scheme, optionally the IMGT numbering scheme. Two or more binding160587589.161 domains may be present that bind to the same or a different RSV-F and / or MPV-F epitope, and a bispecific or multispecific antibody or antigen-binding fragment as provided herein can, in some embodiments, comprise a further RSV-F- and / or MPV-F-specific binding domain, and / or can comprise a binding domain that binds to a different antigen or pathogen altogether. 5 Multispecific antibodies or antigen-binding fragments, particularly bispecific antibodies or antigen-binding fragments, of the present disclosure constructed comprise a first VH and a first VL having any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 10 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259or any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, according to any numbering scheme, optionally according to IMGT scheme. The multispecific antibody or antigen binding fragment 15 further comprises a second VH and a second VL having any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein for a MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2- v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5 antibody; or in any one of SEQ ID NOs: 537-587, particularly any one of SEQ ID NOs: 538, 20 548, 555, 565, 568, and 575 or any one of SEQ ID NOs: 543, 552, 560, 572, and 577; or any MPK65-v2, MPK176-v1.3, MPK201, or RSD5 antibody in Table 1, Table 2; or for any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, and any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81- 25 84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260. The first VH and the first VL together form a first antigen-binding site, and wherein the second VH and the second VL together form a second antigen-binding site. Two or more binding domains may be present that bind to the same or a different RSV- 30 F and / or MPV-F epitope, and a bispecific or multispecific antibody or antigen-binding fragment as provided herein can, in some embodiments, comprise a further RSV-F- and / or MPV-F- specific binding domain, and / or can comprise a binding domain that binds to a different antigen or pathogen altogether.160587589.162 In certain embodiments, an antibody or an antigen-binding fragment is provided that comprises the six CDRs (e.g., as defined by IMGT) and optionally the VH and VL amino acid sequences of an MPK190-v1.3 variant antibody as set forth in Table 1, Table 2, Table 3, or Table 4, for example, SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 5 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, and any one of SEQ ID NOs: 59, 61- 74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, according to any numbering scheme, optionally according to the IMGT numbering scheme. 10 In some embodiments, the antibody or antigen-binding fragment does not comprise the all of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 amino acid sequences of MPK190-v1.3 (ML-190-1.3) antibody , or both the VH and VL of MPK190-v1.3 (ML-190-1.3) antibody, in which components of MPK190-v.1.3 antibody are defined in SEQ ID NOs 1, 202- 204, 94, 211, 214, 215-216, and 209. Optionally, the antibody or antigen-binding fragment may 15 not comprise all CDRs or both the VH and VL of MPK190 antibody or MPK190-v.1. antibody, as defined in SEQ ID NOs: 29, 201-204, 206-209, 1, and 212. In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain, and can be, for example, IgG1m3 comprising M428L and N434S mutations in the heavy chain, or an IgG1 comprising YTE mutations in the constant region. In some embodiments, the 20 antibody or antigen-binding fragment comprises a light chain. A light chain can be, for example, a kappa light chain or a lambda light chain. In any of the presently disclosed embodiments, the antibody or antigen-binding fragment can be multispecific; e.g., bispecific, trispecific, or the like. In some embodiments, the antibody or antigen-binding fragment may further comprise 25 a Fc polypeptide or fragment thereof that comprises or consists of amino acid sequences having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to, or comprises or consists of, the amino acid sequences set forth in and one of SEQ ID NOs: 498-536 and 580-582, 594-601. Unless otherwise specified, human IgG1 Fc 30 mutations discussed herein are identified with reference to the Fc region sequence provided in SEQ ID NO: 499. It will be understood that, for example, production in a mammalian cell line can remove one or more C-terminal lysine of an antibody heavy chain (see, e.g., Liu et al. mAbs 6(5):1145- 1154 (2014)). Production can also remove one or more C-terminal glycine of an160587589.163 antibody heavy chain. Accordingly, an antibody or antigen-binding fragment of the present disclosure can comprise a heavy chain, a CH1-CH3, a CH3, or an Fc polypeptide wherein a C- terminal lysine and / or glycine residue is present or is absent; in other words, encompassed are embodiments where the C-terminal residue of a heavy chain, a CH1-CH3, or an Fc polypeptide 5 is not a lysine or a glycine, and embodiments where a lysine or a glycine is the C-terminal residue. In certain embodiments, a composition comprises a plurality of an antibody and / or an antigen-binding fragment of the present disclosure, wherein one or more antibody or antigen- binding fragment does not comprise a lysine and / or glycine residue at the C-terminal end of the heavy chain, CH1-CH3, or Fc polypeptide, and wherein one or more antibody or antigen- 10 binding fragment comprises a lysine or glycine residue at the C-terminal end of the heavy chain, CH1-CH3, or Fc polypeptide. In certain embodiments, the antibody or antigen-binding fragment comprises a Fc polypeptide, or a fragment thereof. The "Fc" fragment or Fc polypeptide comprises the carboxy-terminal portions (i.e., the CH2 and CH3 domains of IgG) of both antibody H chains 15 held together by disulfides. An Fc may comprise a dimer comprised of two Fc polypeptides (i.e., two CH2-CH3 polypeptides). Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor 20 binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation. As discussed herein, modifications (e.g., amino acid substitutions) may be made to an Fc domain in order to modify (e.g., improve, reduce, or ablate) one or more functionality of an Fc-containing polypeptide (e.g., an antibody of the present disclosure). Such functions include, for example, 25 Fc receptor (FcR) binding, antibody half-life modulation (e.g., by binding to FcRn), ADCC function, protein A binding, protein G binding, and complement binding. Amino acid modifications that modify (e.g., improve, reduce, or ablate) Fc functionalities include, for example, the T250Q / M428L, M252Y / S254T / T256E, H433K / N434F, M428L / N434S, M428L / N434A, E233P / L234V / L235A / G236 + A327G / A330S / P331S, E333A, 30 S239D / A330L / I332E, P257I / Q311, K326W / E333S, S239D / I332E / G236A, N297Q, K322A, S228P, L235E + E318A / K320A / K322A, L234A / L235A (also referred to herein as "LALA"), and L234A / L235A / P329G mutations, which mutations are summarized and annotated in "Engineered Fc Regions", published by InvivoGen (2011) and available online at invivogen.com / PDF / review / review-Engineered-Fc-Regions-160587589.164 invivogen.pdf?utm_source=review&utm_medium=pdf&utm_ campaign=review&utm_content=Engineered-Fc-Regions, and are incorporated herein by reference. For example, to activate the complement cascade, the C1q protein complex can bind to 5 at least two molecules of IgG1 or one molecule of IgM when the immunoglobulin molecule(s) is attached to the antigenic target (Ward, E. S., and Ghetie, V., Ther. Immunol.2 (1995) 77-94). Burton, D. R., described (Mol. Immunol.22 (1985) 161-206) that the heavy chain region comprising amino acid residues 318 to 337 is involved in complement fixation. Duncan, A. R., and Winter, G. (Nature 332 (1988) 738-740), using site directed mutagenesis, reported that 10 Glu318, Lys320 and Lys322 form the binding site to C1q. The role of Glu318, Lys320 and Lys 322 residues in the binding of C1q was confirmed by the ability of a short synthetic peptide containing these residues to inhibit complement mediated lysis. For example, FcR binding can be mediated by the interaction of the Fc moiety (of an antibody) with Fc receptors (FcRs), which are specialized cell surface receptors on cells 15 including hematopoietic cells. Fc receptors belong to the immunoglobulin superfamily, and shown to mediate both the removal of antibody-coated pathogens by phagocytosis of immune complexes, and the lysis of erythrocytes and various other cellular targets (e.g. tumor cells) coated with the corresponding antibody, via antibody dependent cell mediated cytotoxicity (ADCC; Van de Winkel, J. G., and Anderson, C. L., J. Leukoc. Biol.49 (1991) 511-524). FcRs 20 are defined by their specificity for immunoglobulin classes; Fc receptors for IgG antibodies are referred to as FcγR, for IgE as FcεR, for IgA as FcαR and so on and neonatal Fc receptors are referred to as FcRn. Fc receptor binding is described for example in Ravetch, J. V., and Kinet, J. P., Annu. Rev. Immunol.9 (1991) 457-492; Capel, P. J., et al., Immunomethods 4 (1994) 25-34; de Haas, M., et al., J Lab. Clin. Med.126 (1995) 330-341; and Gessner, J. E., et al., Ann. 25 Hematol.76 (1998) 231-248. Cross-linking of receptors by the Fc domain of native IgG antibodies (FcγR) triggers a wide variety of effector functions including phagocytosis, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators, as well as immune complex clearance and regulation of antibody production. Fc moieties providing cross-linking of receptors (e.g., FcγR) 30 are contemplated herein. In humans, three classes of FcγR have been characterized to-date, which are: (i) FcγRI (CD64), which binds monomeric IgG with high affinity and is expressed on macrophages, monocytes, neutrophils and eosinophils; (ii) FcγRII (CD32), which binds complexed IgG with medium to low affinity, is widely expressed, in particular on leukocytes, is believed to be a central player in antibody-mediated immunity, and which can be160587589.165 divided into FcγRIIA, FcγRIIB and FcγRIIC, which perform different functions in the immune system, but bind with similar low affinity to the IgG-Fc, and the ectodomains of these receptors are highly homologous; and (iii) FcγRIII (CD16), which binds IgG with medium to low affinity and has been found in two forms: FcγRIIIA, which has been found on NK cells, macrophages, 5 eosinophils, and some monocytes and T cells, and is believed to mediate ADCC; and FcγRIIIB, which is highly expressed on neutrophils. FcγRIIA is found on many cells involved in killing (e.g. macrophages, monocytes, neutrophils) and seems able to activate the killing process. FcγRIIB seems to play a role in inhibitory processes and is found on B-cells, macrophages and on mast cells and eosinophils. 10 Importantly, it has been shown that 75% of all FcγRIIB is found in the liver (Ganesan, L. P. et al., 2012: "FcγRIIb on liver sinusoidal endothelium clears small immune complexes," Journal of Immunology 189: 4981–4988). FcγRIIB is abundantly expressed on Liver Sinusoidal Endothelium, called LSEC, and in Kupffer cells in the liver and LSEC are the major site of small immune complexes clearance (Ganesan, L. P. et al., 2012: FcγRIIb on liver sinusoidal 15 endothelium clears small immune complexes. Journal of Immunology 189: 4981–4988). In some embodiments, the antibodies disclosed herein and the antigen-binding fragments thereof comprise an Fc polypeptide or fragment thereof for binding to FcγRIIb, in particular an Fc region, such as, for example IgG-type antibodies. Moreover, it is possible to engineer the Fc moiety to enhance FcγRIIB binding by introducing the mutations S267E and 20 L328F as described by Chu, S. Y. et al., 2008: Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Molecular Immunology 45, 3926–3933. Thereby, the clearance of immune complexes can be enhanced (Chu, S., et al., 2014: Accelerated Clearance of IgE In Chimpanzees Is Mediated By Xmab7195, An Fc-Engineered Antibody With Enhanced Affinity 25 For Inhibitory Receptor FcγRIIb. Am J Respir Crit, American Thoracic Society International Conference Abstracts). In some embodiments, the antibodies of the present disclosure, or the antigen-binding fragments thereof, comprise an engineered Fc moiety with the mutations S267E and L328F, in particular as described by Chu, S. Y. et al., 2008: Inhibition of B cell receptor- mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb 30 with Fc-engineered antibodies. Molecular Immunology 45, 3926–3933. On B cells, FcγRIIB may function to suppress further immunoglobulin production and isotype switching to, for example, the IgE class. On macrophages, FcγRIIB is thought to inhibit phagocytosis as mediated through FcγRIIA. On eosinophils and mast cells, the B form may help to suppress activation of these cells through IgE binding to its separate receptor.160587589.166 Regarding FcγRI binding, modification in native IgG of at least one of E233-G236, P238, D265, N297, A327 and P329 reduces binding to FcγRI. IgG2 residues at positions 233- 236, substituted into corresponding positions IgG1 and IgG4, reduces binding of IgG1 and IgG4 to FcγRI by 103-fold and eliminated the human monocyte response to antibody-sensitized red 5 blood cells (Armour, K. L., et al. Eur. J. Immunol.29 (1999) 2613-2624). Regarding FcγRII binding, reduced binding for FcγRIIA is found, e.g., for IgG mutation of at least one of E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292 and K414. Two allelic forms of human FcγRIIA are the "H131" variant, which binds to IgG1 Fc 10 with higher affinity, and the "R131" variant, which binds to IgG1 Fc with low affinity. See, e.g., Bruhns et al., Blood 113:3716-3725 (2009). Regarding FcγRIII binding, reduced binding to FcγRIIIA is found, e.g., for mutation of at least one of E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338 and D376. Mapping of the binding sites on human IgG1 for Fc 15 receptors, the above-mentioned mutation sites, and methods for measuring binding to FcγRI and FcγRIIA, are described in Shields, R. L., et al., J. Biol. Chem.276 (2001) 6591-6604. Two allelic forms of human FcγRIIIA are the "F158" variant, which binds to IgG1 Fc with lower affinity, and the "V158" variant, which binds to IgG1 Fc with higher affinity. See, e.g., Bruhns et al., Blood 113:3716-3725 (2009). 20 Regarding binding to FcγRII, two regions of native IgG Fc appear to be involved in interactions between FcγRIIs and IgGs, namely (i) the lower hinge site of IgG Fc, in particular amino acid residues L, L, G, G (234 – 237, EU numbering), and (ii) the adjacent region of the CH2 domain of IgG Fc, in particular a loop and strands in the upper CH2 domain adjacent to the lower hinge region, e.g. in a region of P331 (Wines, B.D., et al., J. Immunol.2000; 164: 25 5313 – 5318). Moreover, FcγRI appears to bind to the same site on IgG Fc, whereas FcRn and Protein A bind to a different site on IgG Fc, which appears to be at the CH2-CH3 interface (Wines, B.D., et al., J. Immunol.2000; 164: 5313 – 5318). Also contemplated are mutations that increase binding affinity of an Fc polypeptide or fragment thereof of the present disclosure to a (i.e., one or more) Fcγ receptor (e.g., as 30 compared to a reference Fc polypeptide or fragment thereof or containing the same that does not comprise the mutation(s)). See, e.g., Delillo and Ravetch, Cell 161(5):1035-1045 (2015) and Ahmed et al., J. Struc. Biol.194(1):78 (2016), the Fc mutations and techniques of which are incorporated herein by reference.160587589.167 In any of the herein disclosed embodiments, an antibody or antigen-binding fragment can comprise a Fc polypeptide or fragment thereof comprising a mutation selected from G236A; S239D; A330L; and I332E; or a combination comprising any two or more of the same; e.g., S239D / I332E; S239D / A330L / I332E; G236A / S239D / I332E; G236A / A330L / I332E (also 5 referred to herein as "GAALIE"); or G236A / S239D / A330L / I332E. In some embodiments, the Fc polypeptide or fragment thereof does not comprise S239D. In some embodiments, the Fc polypeptide or fragment thereof comprises S at position 239 (EU numbering). In certain embodiments, the Fc polypeptide or fragment thereof may comprise or consist of at least a portion of an Fc polypeptide or fragment thereof that is involved in FcRn 10 binding. In certain embodiments, the Fc polypeptide or fragment thereof comprises one or more amino acid modifications that improve binding affinity for (e.g., enhance binding to) FcRn (e.g., at a pH of about 6.0) and, in some embodiments, thereby extend in vivo half-life of a molecule comprising the Fc polypeptide or fragment thereof (e.g., as compared to a reference Fc polypeptide or fragment thereof or antibody that is otherwise the same but does not comprise 15 the modification(s)). In certain embodiments, the Fc polypeptide or fragment thereof comprises or is derived from a IgG Fc and a half-life-extending mutation comprises any one or more of: M428L; N434S; N434H; N434A; N434S; M252Y; S254T; T256E; T250Q; P257I Q311I; D376V; T307A; E380A (EU numbering). In certain embodiments, a half-life-extending mutation comprises M428L / N434S (also referred to herein as "MLNS", "LS", "_LS", and "- 20 LS"). In particular an antibody or antigen binding fragment thereof having an LS mutation may comprise a heavy chain constant region sequence set forth in any of SEQ ID NOs: 515-520, 527-531, 582, 595, and 597. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the 25 amino acid sequence set forth in SEQ ID NO:251, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:252, and (c) a heavy chain constant region comprising a M428L / N434S mutation, optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOS: 515-520, 527-531, 582, 595, and 597. 30 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:240, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:241, and (c) a heavy chain constant region comprising a M428L / N434S mutation, optionally wherein the160587589.168 heavy chain constant region thereof comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOS: 515-520, 527-531, 582, 595, and 597. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the 5 amino acid sequence set forth in SEQ ID NO:247, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:245, and (c) heavy chain constant region comprising a M428L / N434S mutation, optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOS: 515-520, 527-531, 582, 595, and 597. 10 In certain embodiments, a half-life-extending mutation comprises M252Y / S254T / T256E (also referred to as “YTE”). Although YTE is known to reduce effector functions, the extension in half-life provided by this mutation may prove sufficiently beneficial to outweigh any effector function reduction. Accordingly, the disclosure specifically provides for MPK190-v1.3 variant antibodies containing the YTE mutation. In some embodiments, the 15 antibody or antigen-binding fragment thereof having a YTE mutation comprises a heavy chain constant region comprising, consisting essentially of, or consisting of the amino acid sequence of any one of 580-582, and 594-601. In particular, an antibody having a YTE mutation may comprise a CH2 domain having the sequence set forth in SEQ ID NO: 581, or a CH domain having the sequence set forth in SEQ ID NO: 580, or a CH1-CH2-CH3 region having the 20 sequence set forth in SEQ ID NO:594-601. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:251, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:252, and (c) a 25 heavy chain constant region comprising a M252Y / S254T / T256E mutation, optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOS: 580-582, and 594-601. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the 30 amino acid sequence set forth in SEQ ID NO:240, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:241, and (c) a heavy chain constant region comprising a M252Y / S254T / T256E mutation, optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOS: 580-582, and 594-601.160587589.169 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:247, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:245, and (c) a heavy chain 5 constant region comprising a M252Y / S254T / T256E mutation, optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOS: 580-582, and 594-601. In some embodiments, the antibody or antigen-binding fragment thereof may comprise both an LS mutation (M428L / N434S) and a YTE mutation (M252Y / S254T / T256E). In some 10 embodiments, the antibody or antigen-binding fragment thereof having an LS mutation and a YTE mutation comprises a heavy chain constant region comprising, consisting essentially of, or consisting of the amino acid sequence of any one of SEQ ID NOS: 582, 595, and 597, In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the 15 amino acid sequence set forth in SEQ ID NO:251, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:252, and (c) a heavy chain constant region comprising a M428L / N434S mutation and a M252Y / S254T / T256E mutation, optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in SEQ ID NO:582, 595, and 597. 20 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:240, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:241, and (c) a heavy chain constant region comprising a M428L / N434S mutation and a M252Y / S254T / T256E mutation, 25 optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in SEQ ID NO: 582, 595, and 597. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:247, (b) a VL comprising, consisting essentially 30 of, or consisting of the amino acid sequence set forth in SEQ ID NO:245, and (c) a heavy chain constant region comprising a M428L / N434S mutation and a M252Y / S254T / T256E mutation, optionally wherein the heavy chain constant region comprises, consists essentially of, or consists of the amino acid sequence set forth in SEQ ID NO: 582, 595, and 597.160587589.170 In certain embodiments, a half-life-extending mutation comprises T250Q / M428L. In certain embodiments, a half-life-extending mutation comprises P257I / Q311I. In certain embodiments, a half-life-extending mutation comprises P257I / N434H. In certain embodiments, a half-life-extending mutation comprises D376V / N434H. In certain embodiments, a half-life- 5 extending mutation comprises T307A / E380A / N434A. In certain embodiments, a half-life- extending mutation comprises M428L / N434A (also referred to herein as “MLNA”, “LA”, _LA”, and “-LA”). In some embodiments, the Fc polypeptide or fragment thereof comprising the M428L / N434A mutation comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOS: 521-526 and 532-536. 10 In some embodiments, an antibody or antigen-binding fragment includes a Fc moiety that comprises the substitution mutations M428L / N434S or M428L / N434A. In some embodiments, an antibody or antigen-binding fragment includes a Fc polypeptide or fragment thereof that comprises the substitution mutations G236A / A330L / I332E. In certain embodiments, an antibody or antigen-binding fragment includes a (e.g., IgG) Fc moiety that 15 comprises a G236A mutation, an A330L mutation, and a I332E mutation (GAALIE), and does not comprise a S239D mutation (e.g., comprises a native S at position 239). In particular embodiments, an antibody or antigen-binding fragment includes an Fc polypeptide or fragment thereof that comprises the substitution mutation: M428L / N434S and G236A / A330L / I332E, and, optionally does not comprise S239D (e.g., comprises S at 239). In particular embodiments, 20 an antibody or antigen-binding fragment includes an Fc polypeptide or fragment thereof that comprises the substitution mutation: M428L / N434A and G236A / A330L / I332E, and, optionally does not comprise S239D (e.g., comprises S at 239). In certain embodiments, an antibody or antigen-binding fragment includes a Fc polypeptide or fragment thereof that comprises the substitution mutations: M428L / N434S (or M428L / N434A) and G236A / S239D / A330L / I332E. 25 In some embodiments, an antibody or antigen-binding fragment (described further herein) is provided that comprises, in a(n e.g. human) IgG1 heavy chain, the amino acid mutation(s) set forth in any one of (i)-(xviii): (i) G236A, L328V, and Q295E; (ii) G236A, P230A, and Q295E; (iii) G236A, R292P, and I377N; (iv) G236A, K334A, and Q295E; (v) G236S, R292P, and Y300L; (vi) G236A and Y300L; (vii) G236A, R292P, and Y300L; (viii) 30 G236S, G420V, G446E, and L309T; (ix) G236A and R292P; (x) R292P and Y300L; (xi) G236A and R292P; (xii) Y300L; (xiii) E345K, G236S, L235Y, and S267E; (xiv) E272R, L309T, S219Y, and S267E; (xv) G236Y; (xvi) G236W; (xvii) F243L, G446E, P396L, and S267E; (xviii) G236A, S239D, and H268E, wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat. In certain embodiments, the antibody or160587589.171 antigen-binding fragment is afucosylated. In some embodiments, the antibody or antigen- binding fragment further comprises one or more mutation that enhances binding to a human FcRn, such as M428L and N434S mutations or M428L and N434A mutations (EU numbering) or any other mutation(s) that enhance binding to a human FcRn, such as those described herein. 5 In certain embodiments, the antibody or antigen-binding fragment is afucosylated. In specific embodiments, the antibody or antigen-binding fragment comprises i) a VH and a VL as set forth anywhere herein, respectively; or (iii) a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 as set forth anywhere herein or as determined by any CDL determination scheme disclosed herein, and (A) a Fc polypeptide that comprises the substitution 10 mutations: (i) G236A, L328V, and Q295E; (ii) G236A, P230A, and Q295E; (iii) G236A, R292P, and I377N; (iv) G236A, K334A, and Q295E; (v) G236S, R292P, and Y300L; (vi) G236A and Y300L; (vii) G236A, R292P, and Y300L; (viii) G236S, G420V, G446E, and L309T; (ix) G236A and R292P; (x) R292P and Y300L; (xi) G236A and R292P; (xii) Y300L; (xiii) E345K, G236S, L235Y, and S267E; (xiv) E272R, L309T, S219Y, and S267E; (xv) G236Y; 15 (xvi) G236W; (xvii) F243L, G446E, P396L, and S267E; (xviii) G236A, S239D, and H268E; (xix) M428L / N434S; (xx) M428L / N434A; (xxi) G236A / A330L / I332E / M428L / N434S; (xxii) G236A / A330L / I332E / M428L / N434A; or (xxiii) any two or more of (i)-(xxii); or (B) an Fc moiety that comprises or consists of a Fc polypeptide or fragment thereof that comprises or consists of amino acid sequences having at least 85%, at least 86%, at least 87%, at least 88%, 20 at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any one of SEQ ID NOs: 498- 536, 580-582, 594, and 595, optionally other than naturally occurring variants thereof, or that comprises or consists of, the amino acid sequences set forth in any one of SEQ ID NOs: 498- 536, 580-582, 594-601. 25 In specific embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:251, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:252, and (c) a Fc moiety that comprises the substitution mutations: (i) G236A, L328V, and Q295E; (ii) G236A, P230A, and Q295E; (iii) 30 G236A, R292P, and I377N; (iv) G236A, K334A, and Q295E; (v) G236S, R292P, and Y300L; (vi) G236A and Y300L; (vii) G236A, R292P, and Y300L; (viii) G236S, G420V, G446E, and L309T; (ix) G236A and R292P; (x) R292P and Y300L; (xi) G236A and R292P; (xii) Y300L; (xiii) E345K, G236S, L235Y, and S267E; (xiv) E272R, L309T, S219Y, and S267E; (xv) G236Y; (xvi) G236W; (xvii) F243L, G446E, P396L, and S267E; (xviii) G236A,160587589.172 S239D, and H268E; (xix) M428L / N434S; (xx) M428L / N434A; (xxi) G236A / A330L / I332E / M428L / N434S; (xxii) G236A / A330L / I332E / M428L / N434A; or (xxiii) any two or more of (i)-(xxii); or (B) an Fc moiety that comprises or consists of a Fc polypeptide or fragment thereof that comprises or consists of amino acid sequences having at least 85%, at 5 least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any one of SEQ ID NOs: 498-536, 580-582, 594-601, optionally other than naturally occurring variants thereof, or that comprises or consists of, the amino acid sequences set forth in any one of SEQ ID NOs: 498-536, 580-582, 594-601. 10 In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:240, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:241, and (c) a Fc moiety that comprises the substitution mutations: (i) G236A, L328V, and Q295E; (ii) G236A, P230A, 15 and Q295E; (iii) G236A, R292P, and I377N; (iv) G236A, K334A, and Q295E; (v) G236S, R292P, and Y300L; (vi) G236A and Y300L; (vii) G236A, R292P, and Y300L; (viii) G236S, G420V, G446E, and L309T; (ix) G236A and R292P; (x) R292P and Y300L; (xi) G236A and R292P; (xii) Y300L; (xiii) E345K, G236S, L235Y, and S267E; (xiv) E272R, L309T, S219Y, and S267E; (xv) G236Y; (xvi) G236W; (xvii) F243L, G446E, P396L, and S267E; (xviii) 20 G236A, S239D, and H268E; (xix) M428L / N434S; (xx) M428L / N434A; (xxi) G236A / A330L / I332E / M428L / N434S; (xxii) G236A / A330L / I332E / M428L / N434A; or (xxiii) any two or more of (i)-(xxii); or (B) an Fc moiety that comprises or consists of a Fc polypeptide or fragment thereof that comprises or consists of amino acid sequences having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at 25 least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any one of SEQ ID NOs: 498-536, 580-582, 594-601, optionally other than naturally occurring variants thereof, or that comprises or consists of, the amino acid sequences set forth in any one of SEQ ID NOs: 498-536, 580-582, 594-601. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F 30 and / or MPV-F comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:247, (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:245, and (c) a Fc moiety that comprises the substitution mutations: (i) G236A, L328V, and Q295E; (ii) G236A, P230A, and Q295E; (iii) G236A, R292P, and I377N; (iv) G236A, K334A, and Q295E; (v)160587589.173 G236S, R292P, and Y300L; (vi) G236A and Y300L; (vii) G236A, R292P, and Y300L; (viii) G236S, G420V, G446E, and L309T; (ix) G236A and R292P; (x) R292P and Y300L; (xi) G236A and R292P; (xii) Y300L; (xiii) E345K, G236S, L235Y, and S267E; (xiv) E272R, L309T, S219Y, and S267E; (xv) G236Y; (xvi) G236W; (xvii) F243L, G446E, P396L, and 5 S267E; (xviii) G236A, S239D, and H268E; (xix) M428L / N434S; (xx) M428L / N434A; (xxi) G236A / A330L / I332E / M428L / N434S; (xxii) G236A / A330L / I332E / M428L / N434A; or (xxiii) any two or more of (i)-(xxii); or (B) an Fc moiety that comprises or consists of a Fc polypeptide or fragment thereof that comprises or consists of amino acid sequences having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at 10 least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any one of SEQ ID NOs: 498-536, 580-582, 594-601, optionally other than naturally occurring variants thereof, or that comprises or consists of, the amino acid sequences set forth in any one of SEQ ID NOs: 498-536, 580-582, 594-601; or (C) an Fc moiety according to Table A. 15 In certain embodiments, the antibody or antigen-binding fragment comprises a mutation that alters glycosylation, wherein the mutation that alters glycosylation comprises N297A, N297Q, or N297G, and / or the antibody or antigen-binding fragment is partially or fully aglycosylated and / or is partially or fully afucosylated. Host cell lines and methods of making partially or fully aglycosylated or partially or fully afucosylated antibodies and antigen-binding 20 fragments are known (see, e.g., PCT Publication No. WO 2016 / 181357; Suzuki et al. Clin. Cancer Res.13(6):1875-82 (2007); Huang et al. MAbs 6:1-12 (2018)). An antibody or antigen-binding fragment of the present disclosure can be fucosylated (e.g., comprising one or more fucosyl moiety, and typically comprising a native (wild-type) fucosylation pattern or a fucosylation pattern that includes one or more additional, or fewer, 25 fucosyl moieties as compared to native), or can be afucosylated. In particular, native IgG1 antibodies carry a glycan site at N297, and this is typically the only site where a core fucose moiety may be found in the antibody, though some glycan sites may arise through mutation (e.g. in the variable domains) during antibody development. Fucosylation of an Fc polypeptide or fragment thereof, or of an antibody, can be effected by introducing amino acid mutations to 30 introduce or disrupt a fucosylation site (e.g. a mutation at N297, such as N297Q or N297A, to disrupt formation of a glycan that can include a core fucose moiety), though typically it is preferred to maintain N297 and the glycan thereof, such as by expressing the polypeptide in a host cell which has been genetically engineered to lack the ability (or have an inhibited or compromised ability) to fucosylate the polypeptide; by expressing the polypeptide160587589.174 under conditions in which a host cell is impaired in its ability to fucosylate the polypeptide (e.g., in the presence of 2-fluoro-L-fucose (2FF)), or the like. An afucosylated polypeptide can comprise no fucose moieties, or substantially no fucose moieties, and / or can be expressed by a host cell that is genetically engineered to lack the ability (or have an inhibited or compromised 5 ability) to fucosylate the polypeptide and / or can be expressed under conditions in which a host cell is impaired in its ability to fucosylate the polypeptide (e.g., in the presence of 2-fluoro-L- fucose (2FF)). In some embodiments, a polypeptide does not comprise a core fucose moiety at Asn297. In some embodiments, afucosylated polypeptides have increased binding to FcγRIIIA. In some contexts, addition of 2FF to a culture media comprising host cells expressing an 10 antibody results in about 85% or more of the antibodies not carrying a fucose moiety. Accordingly, a plurality of antibodies may be described as “afucosylated” when the plurality was produced in the presence of 2FF or like reagent. In some contexts, a plurality of polypeptides or antibodies may be described as, for example, afucosylated, meaning that about 85% or more of the single polypeptide or antibody molecules of the plurality do not comprise a 15 fucose moiety. In certain preferred embodiments, an afucosylated antibody or polypeptide or a population or a plurality thereof comprises an asparagine (N) at EU position 297. Fucosylation or lack thereof can be assessed using, for example, mass spectrometry (e.g. Electrospray mass spectrometry (ESI-MS)). In some embodiments, compositions are provided that comprise a plurality of any one or more of the presently disclosed polypeptides, wherein the composition 20 comprises afucosylated polypeptides. In certain embodiments, the antibody or antigen-binding fragment is capable of eliciting continued protection in vivo in a subject even once no detectable levels of the antibody or antigen-binding fragment can be found in the subject (i.e., when the antibody or antigen-binding fragment has been cleared from the subject following administration). Such protection is 25 referred to herein as a vaccinal effect. Without wishing to be bound by theory, it is believed that dendritic cells can internalize complexes of antibody and antigen and thereafter induce or contribute to an endogenous immune response against antigen. In certain embodiments, an antibody or antigen-binding fragment comprises one or more modifications, such as, for example, mutations in the Fc comprising G236A, A330L, and I332E, that are capable of 30 activating dendritic cells that may induce, e.g., T cell immunity to the antigen. In any of the presently disclosed embodiments, the antibody or antigen-binding fragment comprises a Fc polypeptide or a fragment thereof, including a CH2 (or a fragment thereof, a CH3 (or a fragment thereof), or a CH2 and a CH3, wherein the CH2, the CH3, or both can be of any isotype and may contain amino acid substitutions or other160587589.175 modifications as compared to a corresponding wild-type CH2 or CH3, respectively. In certain embodiments, a Fc of the present disclosure comprises two CH2-CH3 polypeptides that associate to form a dimer. In certain embodiments, the antibody or antigen-binding fragment comprises an 5 MPK190v1.3 variant antibody with variations as noted in Table 1, Table 2, Table 3, or Table 4, and a HC amino acid sequence and LC amino acid sequence otherwise as set forth in Table 1 for MPK190-rIgG1-LS, MPK190-v1.3-rIG1m17,1-LS, MPK190-v1.3-rIgG1-YTE or MPK 190-v20.6, MPK190-v11.3, MPK190-v11.6, MPK190-v9.6, or MPK190-v20.3 with similar LS or YTE modifications, and may be encoded by nucleic acids having the corresponding 10 sequences set forth in Table 1. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:251, and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:252, optionally wherein the heavy chain further comprises a 15 M428L / N434S mutation, a M252Y / S254T / T256E, or both a M428L / N434S mutation and a M252Y / S254T / T256E. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:240, and (b) a light chain comprising, 20 consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:241, optionally wherein the heavy chain further comprises a M428L / N434S mutation, a M252Y / S254T / T256E, or both a M428L / N434S mutation and a M252Y / S254T / T256E. In certain embodiments, the antibody or antigen-binding fragment that binds RSV-F and / or MPV-F comprises: (a) a heavy chain comprising, consisting essentially of, or consisting 25 of the amino acid sequence set forth in SEQ ID NO:247, and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:245, optionally wherein the heavy chain further comprises a M428L / N434S mutation, a M252Y / S254T / T256E, or both a M428L / N434S mutation and a M252Y / S254T / T256E. In certain embodiments, an antibody or antigen-binding fragment of the present disclosure 30 comprises an Fc variant selected from the Fc variants summarized in Table A (see also PCT Publication No. WO 2022 / 251119). In certain embodiments, the Fc variant, or the antibody or antigen-binding fragment, is fucosylated. In other embodiments, the Fc variant, or the antibody or antigen-binding fragment, is afucosylated. Table A. Fc Variants (fucosylated unless otherwise indicated) and Properties160587589.176 Thereof 160587589.177 In some embodiments, an anti-parvovirus antibody or antigen-binding fragment is provided that comprises, in a(n e.g. human) IgG1 heavy chain, the amino acid mutation(s) set forth in any one of (i)-(xviii): (i) G236A, L328V, and Q295E; (ii) G236A, P230A, and Q295E; (iii) G236A, R292P, and I377N; (iv) G236A, K334A, and Q295E; (v) G236S, R292P, and 5 Y300L; (vi) G236A and Y300L; (vii) G236A, R292P, and Y300L; (viii) G236S, G420V, G446E, and L309T; (ix) G236A and R292P; (x) R292P and Y300L; (xi) G236A and R292P; (xii) Y300L; (xiii) E345K, G236S, L235Y, and S267E; (xiv) E272R, L309T, S219Y, and S267E; (xv) G236Y; (xvi) G236W; (xvii) F243L, G446E, P396L, and S267E; (xviii) G236A, S239D, and H268E, wherein the numbering of amino acid residues is according to the EU index 10 as set forth in Kabat. In certain embodiments, the antibody or antigen-binding fragment is afucosylated. In some embodiments, the antibody or antigen-binding fragment further comprises one or more mutation that enhances binding to a human FcRn, such as M428L and N434S mutations or M428L and N434A mutations (EU numbering) or any other mutation(s) that enhance binding to a human FcRn, such as those described herein. In certain embodiments, 15 the antibody or antigen-binding fragment is afucosylated. In any of the presently disclosed embodiments, the antibody or antigen-binding fragment comprises a Fc polypeptide or a fragment thereof, including a CH2 (or a fragment thereof, a CH3 (or a fragment thereof), or a CH2 and a CH3, wherein the CH2, the160587589.178 CH3, or both can be of any isotype and may contain amino acid substitutions or other modifications as compared to a corresponding wild-type CH2 or CH3, respectively. In certain embodiments, a Fc of the present disclosure comprises two CH2-CH3 polypeptides that associate to form a dimer. 5 In any of the presently disclosed embodiments, the antibody or antigen-binding fragment comprises a Fc polypeptide or a fragment thereof, including a CH2 (or a fragment thereof, a CH3 (or a fragment thereof), or a CH2 and a CH3, wherein the CH2, the CH3, or both can be of any isotype and may contain amino acid substitutions or other modifications as compared to a corresponding wild-type CH2 or CH3, respectively. In certain embodiments, a 10 Fc of the present disclosure comprises two CH2-CH3 polypeptides that associate to form a dimer. In some embodiments, the antibody or antigen-binding fragment includes a VH comprised in a Fd that further comprises the heavy chain constant domain 1 (CH1) amino acid sequence set forth in SEQ ID NO.:92 or 98. 15 In some embodiments, the antibody or antigen-binding fragment includes a VL comprised in a LC that further comprises a lambda light chain constant domain or a kappa light chain constant domain. In some embodiments, the antibody or antigen-binding fragment includes a VL comprised in a LC that further comprises the light chain constant domain (CL) amino acid 20 sequence set forth in any one of SEQ ID NOs.:95 and 99-105. In some embodiments, the antibody or antigen-finding fragment includes a Fd according to SEQ ID NO: 9. In some embodiments, the antibody or antigen-binding fragment includes a LC variant according to any one of SEQ ID NOs: 58, 60, 75, 80, 85, and 90. 25 Some embodiments include both a VH and a VL as described in the preceding two paragraphs. In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:240; and (ii) a light chain polypeptide comprising, consisting 30 essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:241. In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:251; and (ii) a light chain polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:22.160587589.179 In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:247; and (ii) a light chain polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:245. 5 In any of the presently disclosed embodiments, the antibody or antigen-binding fragment can be monoclonal. The term "monoclonal antibody" (mAb) as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present, in some cases in minor amounts. Monoclonal 10 antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that include different antibodies directed against different epitopes, each monoclonal antibody is directed against a single epitope of the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The term "monoclonal" is not to be construed 15 as requiring production of the antibody by any particular method. For example, monoclonal antibodies useful in the present invention may be prepared by the hybridoma methodology first described by Kohler et al., Nature 256:495 (1975), or may be made using recombinant DNA methods in bacterial, eukaryotic animal, or plant cells (see, e.g., U.S. Pat. No.4,816,567). Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques 20 described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991), for example. Monoclonal antibodies may also be obtained using methods disclosed in PCT Publication No. WO 2004 / 076677A2. Antibodies and antigen-binding fragments of the present disclosure include "chimeric antibodies" in which a portion of the heavy and / or light chain is identical with or homologous to 25 corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see, U.S. Pat. Nos.4,816,567; 5,530,101 and 30 7,498,415; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). For example, chimeric antibodies may comprise human and non-human residues. Furthermore, chimeric antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al.,160587589.180 Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol.2:593-596 (1992). Chimeric antibodies also include primatized and humanized antibodies. A "humanized antibody" is generally considered to be a human antibody that has one or more amino acid residues introduced into it from a source that is non-human. These non-human 5 amino acid residues are typically taken from a variable domain. Humanization may be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534- 1536 (1988)), by substituting non-human variable sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. 10 Pat. Nos.4,816,567; 5,530,101 and 7,498,415) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In some instances, a "humanized" antibody is one which is produced by a non-human cell or animal and comprises human sequences, e.g., HCdomains. A "human antibody" is an antibody containing only sequences that are present in an 15 antibody that is produced by a human (i.e., sequences that are encoded by human antibody- encoding genes). However, as used herein, human antibodies may comprise residues or modifications not found in a naturally occurring human antibody (e.g., an antibody that is isolated from a human), including those modifications and variant sequences described herein. These are typically made to further refine or enhance antibody performance. In some instances, 20 human antibodies are produced by transgenic animals. For example, see U.S. Pat. Nos. 5,770,429; 6,596,541 and 7,049,426. In certain embodiments, an antibody or antigen-binding fragment of the present disclosure is chimeric, humanized, or human. In some embodiments, various pharmacokinetic ("PK") parameters are used to describe 25 or characterize the antibodies or antigen-binding fragments provided herein. Details regarding collection of antibody serum concentrations for purpose of evaluating PK parameters are described in association with the Examples herein. The term "t1 / 2" or "half-life" refers to the elimination half-life of the antibody included in the pharmaceutical composition administered to a subject. The term "Clast" generally refers to the last measurable plasma concentration (i.e., 30 subsequent thereto, the substance is not present at a measurable concentration in plasma). Polynucleotides, Vectors, and Host cells In another aspect, the present disclosure provides isolated polynucleotides that encode any of the presently disclosed antibodies or an antigen-binding fragment, or a160587589.181 portion thereof (e.g., a CDR, a VH, a VL, a heavy chain, or a light chain). In certain embodiments, the polynucleotide is codon-optimized for expression in a host cell. Once a coding sequence is known or identified, codon optimization can be performed using known techniques and tools, e.g., using the GenScript® OptimiumGeneTMtool, or the like). Codon- 5 optimized sequences include sequences that are partially codon-optimized (i.e., one or more codon is optimized for expression in the host cell) and those that are fully codon-optimized. It will also be appreciated that polynucleotides encoding antibodies and antigen-binding fragments of the present disclosure may possess different nucleotide sequences while still encoding a same antibody or antigen-binding fragment due to, for example, the degeneracy of 10 the genetic code, splicing, and the like. In any of the presently disclosed embodiments, the polynucleotide can comprise deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). In some embodiments, the RNA comprises messenger RNA (mRNA). In specific embodiments, polynucleotides encoding antibodies or antigen-binding 15 fragments that bind RSV-F and / or MPV-F comprise nucleotides encoding a VH of any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259 in a polynucleotide sequence and / or nucleotides encoding a VL of any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 20 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260in a polynucleotide sequence, and / or at least two portions of any of the preceding sequences encoding a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL1, and / or a functional variant thereof comprising nucleotides that encode the same protein or a protein with one, two, or three amino acid substitutions, one or more of which substitutions is optionally a 25 conservative substitution and / or is a substitution to a germline-encoded amino acid, and / or a nucleotide sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the nucleotide sequence. Additional polynucleotide sequences encoding antibodies or antigen-binding fragments are provided in Tables 1 and 2. In specific embodiments, polynucleotides encoding antibodies or antigen-binding 30 fragments that bind RSV-F and / or MPV-F comprise nucleotides encoding a VH of any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, in a polynucleotide sequence and / or nucleotides encoding a VL of any one of SEQ ID NOs: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94,160587589.182 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260 in a polynucleotide sequence, and / or at least two portions of any of the preceding sequences encoding a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL1, and / or a functional variant thereof comprising nucleotides that encode the same protein or a 5 protein with one, two, or three amino acid substitutions, one or more of which substitutions is optionally a conservative substitution and / or is a substitution to a germline-encoded amino acid, and / or a nucleotide sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the nucleotide sequence. In specific embodiments, polynucleotides encoding antibodies or antigen-binding 10 fragments that bind RSV-F and / or MPV-F comprise nucleotides encoding a VH of SEQ ID NO:251 in a polynucleotide sequence and / or nucleotides encoding a VL of SEQ ID NO:252 in a polynucleotide sequence, and / or at least two portions of any of the preceding sequences encoding a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL1, and / or a functional variant thereof comprising nucleotides that encode the same protein or a protein with one, two, 15 or three amino acid substitutions, one or more of which substitutions is optionally a conservative substitution and / or is a substitution to a germline-encoded amino acid, and / or a nucleotide sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the nucleotide sequence. In specific embodiments, polynucleotides encoding antibodies or antigen-binding 20 fragments that bind RSV-F and / or MPV-F comprise nucleotides encoding a VH of SEQ ID NO:190 in a polynucleotide sequence and / or nucleotides encoding a VL of SEQ ID NO:191 in a polynucleotide sequence, and / or at least two portions of any of the preceding sequences encoding a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL1, and / or a functional variant thereof comprising nucleotides that encode the same protein or a protein with one, two, 25 or three amino acid substitutions, one or more of which substitutions is optionally a conservative substitution and / or is a substitution to a germline-encoded amino acid, and / or a nucleotide sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the nucleotide sequence. In specific embodiments, polynucleotides encoding antibodies or antigen-binding 30 fragments that bind RSV-F and / or MPV-F comprise nucleotides encoding a VH of SEQ ID NO:197 in a polynucleotide sequence and / or nucleotides encoding a VL of SEQ ID NO:195 in a polynucleotide sequence, and / or at least two portions of any of the preceding sequences encoding a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL1, and / or a functional variant thereof comprising nucleotides that encode the same protein or a protein160587589.183 with one, two, or three amino acid substitutions, one or more of which substitutions is optionally a conservative substitution and / or is a substitution to a germline-encoded amino acid, and / or a nucleotide sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the nucleotide sequence. 5 Vectors are also provided, wherein the vectors comprise or contain a polynucleotide as disclosed herein (e.g., a polynucleotide that encodes an antibody or antigen-binding fragment that binds to RSV-F and / or MPV-F). A vector can comprise any one or more of the vectors disclosed herein. In particular embodiments, a vector is provided that comprises a DNA plasmid construct encoding the antibody or antigen-binding fragment, or a portion thereof (e.g., 10 so-called "DMAb"; see, e.g., Muthumani et al., J Infect Dis.214(3):369-378 (2016); Muthumani et al., Hum Vaccin Immunother 9:2253-2262 (2013)); Flingai et al., Sci Rep. 5:12616 (2015); and Elliott et al., NPJ Vaccines 18 (2017), which antibody-coding DNA constructs and related methods of use, including administration of the same, are incorporated herein by reference). In certain embodiments, a DNA plasmid construct comprises a single 15 open reading frame encoding a heavy chain and a light chain (or a VH and a VL) of the antibody or antigen-binding fragment, wherein the sequence encoding the heavy chain and the sequence encoding the light chain are optionally separated by polynucleotide encoding a protease cleavage site and / or by a polynucleotide encoding a self-cleaving peptide. In some embodiments, the substituent components of the antibody or antigen-binding fragment are 20 encoded by a polynucleotide comprised in a single plasmid. In other embodiments, the substituent components of the antibody or antigen-binding fragment are encoded by a polynucleotide comprised in two or more plasmids (e.g., a first plasmid comprises a polynucleotide encoding a heavy chain, VH, or VH+CH, and a second plasmid comprises a polynucleotide encoding the cognate light chain, VL, or VL+CL). In certain embodiments, a 25 single plasmid comprises a polynucleotide encoding a heavy chain and / or a light chain from two or more antibodies or antigen-binding fragments of the present disclosure. An exemplary expression vector is pVax1, available from Invitrogen®. A DNA plasmid of the present disclosure can be delivered to a subject by, for example, electroporation (e.g., intramuscular electroporation), or with an appropriate formulation (e.g., hyaluronidase). 30 In a further aspect, the present disclosure also provides a host cell expressing an antibody or antigen-binding fragment according to the present disclosure; or comprising or containing a vector or polynucleotide according to the present disclosure. Examples of such cells include but are not limited to, eukaryotic cells, e.g., yeast cells, animal cells, insect cells, plant cells; and prokaryotic cells, including E. coli. In160587589.184 some embodiments, the cells are mammalian cells. In certain such embodiments, the cells are a mammalian cell line such as CHO cells (e.g., DHFR- CHO cells (Urlaub et al., PNAS 77:4216 (1980)), human embryonic kidney cells (e.g., HEK293T cells), PER.C6 cells, Y0 cells, Sp2 / 0 cells. NS0 cells, human liver cells, e.g. Hepa RG cells, myeloma cells or hybridoma cells. 5 Other examples of mammalian host cell lines include mouse sertoli cells (e.g., TM4 cells); monkey kidney CV1 line transformed by SV40 (COS-7); baby hamster kidney cells (BHK); African green monkey kidney cells (VERO-76); monkey kidney cells (CV1); human cervical carcinoma cells (HELA); human lung cells (W138); human liver cells (Hep G2); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); mouse mammary tumor (MMT 060562); TRI 10 cells; MRC 5 cells; and FS4 cells. Mammalian host cell lines suitable for antibody production also include those described in, for example, Yazaki and Wu, Methods in Molecular Biology, Vol.248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp.255-268 (2003). In certain embodiments, a host cell is a prokaryotic cell, such as an E. coli. The expression of peptides in prokaryotic cells such as E. coli is well established (see, e.g., 15 Pluckthun, A. Bio / Technology 9:545-551 (1991). For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237; 5,789,199; and 5,840,523. In particular embodiments, the cell may be transfected with a vector according to the 20 present description with an expression vector. The term "transfection" refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g. mRNA) molecules, into cells, such as into eukaryotic cells. In the context of the present description, the term "transfection" encompasses any method known to the skilled person for introducing nucleic acid molecules into cells, such as into eukaryotic cells, including into mammalian cells. Such methods encompass, for 25 example, electroporation, lipofection, e.g., based on cationic lipids and / or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or transfection based on cationic polymers, such as DEAE-dextran or polyethylenimine, etc. In certain embodiments, the introduction is non-viral. Moreover, host cells of the present disclosure may be transfected stably or transiently 30 with a vector according to the present disclosure, e.g. for expressing an antibody, or an antigen- binding fragment, according to the present disclosure. In such embodiments, the cells may be stably transfected with the vector as described herein. Alternatively, cells may be transiently transfected with a vector according to the present disclosure encoding an antibody or antigen-160587589.185 binding fragment as disclosed herein. In any of the presently disclosed embodiments, a polynucleotide may be heterologous to the host cell. Accordingly, the present disclosure also provides recombinant host cells that heterologously express an antibody or antigen-binding fragment of the present disclosure. For 5 example, the cell may be of a species that is different to the species from which the antibody was fully or partially obtained (e.g., CHO cells expressing a human antibody or an engineered human antibody). In some embodiments, the cell type of the host cell does not express the antibody or antigen-binding fragment in nature. Moreover, the host cell may impart a post- translational modification (PTM; e.g., glycosylation or fucosylation), or a lack thereof, on the 10 antibody or antigen-binding fragment that is not present in a native state of the antibody or antigen-binding fragment (or in a native state of a parent antibody from which the antibody or antigen binding fragment was engineered or derived). Such a PTM, or a lack thereof, may result in a functional difference (e.g., reduced immunogenicity). Accordingly, an antibody or antigen-binding fragment of the present disclosure that is produced by a host cell as disclosed 15 herein may include one or more post-translational modification that is distinct from the antibody (or parent antibody) in its native state (e.g., a human antibody produced by a host cell can comprise one or more post-translational modification, or can include fewer post- translational modification(s), such that it is distinct from the antibody when isolated from the human and / or produced by the native human B cell or plasma cell). 20 Insect cells useful expressing a binding protein of the present disclosure are known in the art and include, for example, Spodoptera frugipera Sf9 cells, Trichoplusia ni BTI-TN5B1-4 cells, and Spodoptera frugipera SfSWT01 "MimicTM" cells. See, e.g., Palmberger et al., J. 166 (2011). Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera 25 frugiperda cells. Eukaryotic microbes such as filamentous fungi or yeast are also suitable hosts for cloning or expressing protein-encoding vectors, and include fungi and yeast strains with "humanized" glycosylation pathways, resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech.22:1409-1414 (2004); Li et 30 al., Nat. Biotech.24:210-215 (2006). Plant cells can also be utilized as hosts for expressing an antibody or antigen-binding fragment of the present disclosure. For example, PLANTIBODIES™ technology (described in, for example, U.S. Pat. Nos.5,959,177; 6,040,498; 6,420,548; 7,125,978; and 6,417,429) employs transgenic plants to produce antibodies.160587589.186 In certain embodiments, the host cell comprises a mammalian cell. In particular embodiments, the host cell is a CHO cell, an ExpiCHO cell, a HEK293 cell, a PER.C6 cell, a Y0 cell, a Sp2 / 0 cell, a NS0 cell, a human liver cell, a myeloma cell, or a hybridoma cell. In a related aspect, the present disclosure provides methods for producing an antibody 5 or antigen-binding fragment, wherein the methods comprise culturing a host cell of the present disclosure under conditions and for a time sufficient to produce the antibody, or the antigen- binding fragment. Methods useful for isolating and purifying recombinantly produced antibodies, by way of example, may include obtaining supernatants from suitable host cell / vector systems that secrete the recombinant antibody into culture media and then 10 concentrating the media using a commercially available filter. Following concentration, the concentrate may be applied to a single suitable purification matrix or to a series of suitable matrices, such as an affinity matrix or an ion exchange resin. One or more reverse phase HPLC steps may be employed to further purify a recombinant polypeptide. These purification methods may also be employed when isolating an immunogen from its natural environment. 15 Methods for large scale production of one or more of the isolated / recombinant antibody described herein include batch cell culture, which is monitored and controlled to maintain appropriate culture conditions. Purification of soluble antibodies may be performed according to methods described herein and known in the art and that comport with laws and guidelines of domestic and foreign regulatory agencies. 20 Compositions Also provided herein are compositions that comprise a presently disclosed antibody, antigen-binding fragment, polynucleotide, vector, or host cell, singly or in any combination, and can further comprise a pharmaceutically acceptable carrier, excipient, or diluent. Such 25 compositions, as well as carriers, excipients, and diluents, are discussed in further detail herein. In some embodiments, the composition includes two or more non-identical antibodies or antigen-binding fragments thereof, one of which is described in Table 1, Table 2, Table 3, or Table 4, has a VH and / or VL according to an antibody described in Table 1, Table 2, Table 3, or Table 4, or having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity 30 thereto, or having a combination of CDRH1-3 and / or CDRL1-3 (according to any numbering scheme, particularly IMGT) according to any antibody described in Table 1, Table 2, Table 3, or Table 4, other than an MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2- v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5 as described in Table 1, Table 2, Table 3, or Table 4,. In some embodiments, the CDRH1-3 and / or160587589.187 CDRL1-3 are according to any one of SEQ ID NOs.:1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259, and / or nucleotides any one of SEQ ID NOs: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 5 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, respectively. The second antibody or antigen-binding fragment thereof of which composition is an MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5 antibody described in Table 2 and Table 10 1, or having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity thereto, or having a combination of CDRH1-3 and / or CDRL1-3 (according to any numbering scheme, particularly IMGT) according to an MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5 antibody described in Table 2 and Table 1, or an antibody or antigen-binding fragment having 15 CDRH1-3 and / or CDRL1-3 of any one of SEQ ID NOS: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259 and / or any one of SEQ ID NOS: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260. 20 In some embodiments, all CDRs or, optionally, both the VH and VL, of the first and second antibodies are not identical. Also provided herein are compositions that comprise a presently disclosed antibody, antigen-binding fragment, polynucleotide, vector, or host cell, singly or in any combination, and can further comprise a pharmaceutically acceptable carrier, excipient, or diluent. Such 25 compositions, as well as carriers, excipients, and diluents, are discussed in further detail herein. In some embodiments, the composition includes two or more antibodies or antigen-binding fragments thereof, one of which has any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein in any one of SEQ ID NOS: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 30 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259 or any one of SEQ ID NOS: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, or having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity thereto, or160587589.188 having a combination of CDRH1-3 and / or CDRL1-3 (according to any numbering scheme, particularly IMGT) according to any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein in any one of SEQ ID NOS: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 5 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259 or any one of SEQ ID NOS: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, and the second of which is an MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 10 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5 antibody described in Table 2 and Table 1, or having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity thereto, or having a combination of CDRH1-3 and / or CDRL1-3 (according to any numbering scheme, particularly IMGT) according to an MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65- v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or 15 RSD5 antibody described in Table 2 and Table 1. Also provided herein are compositions that comprise a presently disclosed antibody, antigen-binding fragment, polynucleotide, vector, or host cell, singly or in any combination, and can further comprise a pharmaceutically acceptable carrier, excipient, or diluent. Such compositions, as well as carriers, excipients, and diluents, are discussed in further detail herein. 20 In some embodiments, the composition includes two or more antibodies or antigen-binding fragments thereof, one of which has any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 25 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259or any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, or having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity thereto, or having a combination of CDRH1-3 and / or CDRL1-3 (according to any numbering scheme, particularly IMGT) 30 according to any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259or any one of SEQ ID NOs.: 59, 61-74,160587589.189 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, and the second of which has any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein in any one of SEQ ID NOs: 5 537-587, particularly any one of SEQ ID NOs: 538, 548, 555, 565, 568, and 575 or any one of SEQ ID NOs: 543, 552, 560, 572, and 577, or having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity thereto, or having a combination of CDRH1-3 and / or CDRL1-3 (according to any numbering scheme, particularly IMGT) according to any combination of the VH and VL sequences and / or any combination of the CDRH1, CDRH2, CDRH3, CDRL1, 10 CDRL2, and CDRL3 sequences disclosed herein in any one of SEQ ID NOs: 537-587, particularly any one of SEQ ID NOs: 538, 548, 555, 565, 568, and 575 or any one of SEQ ID NOs: 543, 552, 560, 572, and 577. In some embodiments including two antibodies or antigen-binding fragments thereof, one antibody may specifically bind both RSV and MPV, while the second antibody specifically 15 binds only RSV or MPV. In other embodiments, one antibody may specifically bind only RSV while the second antibody specifically binds only MPV. In still other embodiments both antibodies may bind both RSV and MPV, only RSV, or only MPV, more particularly the RSV-only- binding antibody may be any MPK65-v2, MPK176, MPK201, or RSD5 antibody disclosed in Table 1, Table 2. 20 In certain embodiments, the two antibodies or antigen-binding fragment thereof may exhibit improved or synergistic neutralization or prevention or / treatment of infection by RSV and / or MPV. In certain embodiments, a composition comprises a first vector comprising a first plasmid, and a second vector comprising a second plasmid, wherein the first plasmid comprises 25 a polynucleotide encoding a heavy chain, VH, or VH+CH, and a second plasmid comprises a polynucleotide encoding the cognate light chain, VL, or VL+CL of the antibody or antigen- binding fragment. In certain embodiments, a composition comprises a polynucleotide (e.g., mRNA) coupled to a suitable delivery vehicle or carrier. Exemplary vehicles or carriers for administration to a human subject include a lipid or lipid-derived delivery vehicle, such as a 30 liposome, solid lipid nanoparticle, oily suspension, submicron lipid emulsion, lipid microbubble, inverse lipid micelle, cochlear liposome, lipid microtubule, lipid microcylinder, or lipid nanoparticle (LNP) or a nanoscale platform (see, e.g., Li et al. Wilery Interdiscip Rev. Nanomed Nanobiotechnol.11(2):e1530 (2019)). Principles, reagents, and techniques for designing appropriate mRNA and formulating mRNA-LNP and delivering the same are160587589.190 described in, for example, Pardi et al. (J Control Release 217345-351 (2015)); Thess et al. (Mol Ther 23: 1456-1464 (2015)); Thran et al. (EMBO Mol Med 9(10):1434-1448 (2017); Kose et al. (Sci. Immunol.4 eaaw6647 (2019); and Sabnis et al. (Mol. Ther.26:1509-1519 (2018)), which techniques, include capping, codon optimization, nucleoside modification, purification of 5 mRNA, incorporation of the mRNA into stable lipid nanoparticles (e.g., ionizable cationic lipid / phosphatidylcholine / cholesterol / PEG-lipid; ionizable lipid:distearoyl PC:cholesterol:polyethylene glycol lipid), and subcutaneous, intramuscular, intradermal, intravenous, intraperitoneal, and intratracheal administration of the same, are incorporated herein by reference. 10 In some embodiments, the composition includes two or more antibodies or antigen- binding fragment thereof as described herein in Table 1, Table 2, Table 3, or Table 4 having a VH and / or a VL according to an antibody described in Table 1, Table 2, Table 3, or Table 4, or having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity thereto, or having a combination of CDRH1-3 and / or CDRL1-3 according to any antibody described in 15 Table 1, Table 2, Table 3, or Table 4, other than an MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5 antibody. Methods and Uses 20 Also provided herein are methods for use of an antibody or antigen-binding fragment, nucleic acid, vector, cell, or composition of the present disclosure in the diagnosis of a RSV and / or MPV infection (e.g., in a human subject, or in a sample obtained from a human subject). Methods of diagnosis (e.g., in vitro, ex vivo) may include contacting an antibody, antibody fragment (e.g., antigen binding fragment) with a sample. Such samples may be 25 isolated from a subject, for Example 5 isolated tissue sample taken from, for example, nasal passages, sinus cavities, salivary glands, lung, liver, pancreas, kidney, ear, eye, placenta, alimentary tract, heart, ovaries, pituitary, adrenals, thyroid, brain, skin or blood. The methods of diagnosis may also include the detection of an antigen / antibody complex, in particular following the contacting of an antibody or antibody fragment with a sample. Such a detection 30 step can be performed at the bench, i.e. without any contact to the human or animal body. Examples of detection methods are well-known to the person skilled in the art and include, e.g., ELISA (enzyme-linked immunosorbent assay), including direct, indirect, and sandwich ELISA. Also provided herein are methods of treating a subject using an antibody or antigen- binding fragment of the present disclosure, or a composition comprising the same, wherein the160587589.191 subject has, is believed to have, or is at risk for having an infection by a RSV and / or a MPV. "Treat," "treatment," or "ameliorate" refers to medical management of a disease, disorder, or condition of a subject (e.g., a human or non-human mammal, such as a primate, horse, cat, dog, goat, mouse, or rat). In general, an appropriate dose or treatment regimen comprising an 5 antibody or composition of the present disclosure is administered in an amount sufficient to elicit a therapeutic or prophylactic benefit. Therapeutic or prophylactic / preventive benefit includes improved clinical outcome; lessening or alleviation of symptoms associated with a disease; decreased occurrence of symptoms; improved quality of life; longer disease-free status; diminishment of extent of disease, stabilization of disease state; delay or prevention of disease 10 progression; remission; survival; prolonged survival; or any combination thereof. In certain embodiments, therapeutic or prophylactic / preventive benefit includes reduction or prevention of hospitalization for treatment of a RSV and / or MPV infection (i.e., in a statistically significant manner). In certain embodiments, therapeutic or prophylactic / preventive benefit includes a reduced duration of hospitalization for treatment of a RSV and / or a MPV infection (i.e., in a 15 statistically significant manner). In certain embodiments, therapeutic or prophylactic / preventive benefit includes a reduced or abrogated need for respiratory intervention, such as intubation and / or the use of a respirator device. In certain embodiments, therapeutic or prophylactic / preventive benefit includes reversing a late-stage disease pathology and / or reducing mortality. 20 A "therapeutically effective amount" or "effective amount" of an antibody, antigen- binding fragment, polynucleotide, vector, host cell, or composition of this disclosure refers to an amount of the composition or molecule sufficient to result in a therapeutic effect, including improved clinical outcome; lessening or alleviation of symptoms associated with a disease; decreased occurrence of symptoms; improved quality of life; longer disease-free status; 25 diminishment of extent of disease, stabilization of disease state; delay of disease progression; remission; survival; or prolonged survival in a statistically significant manner. When referring to an individual active ingredient, administered alone, a therapeutically effective amount refers to the effects of that ingredient or cell expressing that ingredient alone. When referring to a combination, a therapeutically effective amount refers to the combined amounts of active 30 ingredients or combined adjunctive active ingredient with a cell expressing an active ingredient that results in a therapeutic effect, whether administered serially, sequentially, or simultaneously. Accordingly, in certain embodiments, methods are provided for treating a RSV and / or MPV infection in a subject, wherein the methods comprise administering to the160587589.192 subject an effective amount of an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition as disclosed herein. Subjects that can be treated by the present disclosure are, in general, human and other primate subjects, such as monkeys and apes for veterinary medicine purposes. Other model 5 organisms, such as mice and rats, may also be treated according to the present disclosure. In any of the aforementioned embodiments, the subject may be a human subject. The subjects can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects. A number of criteria are believed to contribute to high risk for severe symptoms or 10 death associated with a RSV and / or MPV infection. These include, but are not limited to, age, occupation, general health, pre-existing health conditions, locale, and lifestyle habits. In some embodiments, a subject treated according to the present disclosure comprises one or more risk factors. In certain embodiments, a human subject treated according to the present disclosure is 15 an infant, a child, a young adult, an adult of middle age, or an elderly person. In certain embodiments, a human subject treated according to the present disclosure is less than 1 year old, or is 1 to 5 years old, or is between 5 and 125 years old (e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 125 years old, including any and all ages therein or therebetween). In certain embodiments, a human subject treated 20 according to the present disclosure is 0-19 years old, 20-44 years old, 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old, or older. Persons of middle, and especially of elderly age are believed to be at particular risk. In particular embodiments, the human subject is 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old, or older. In some embodiments, the human subject is male. In some embodiments, the 25 human subject is female. In certain embodiments, a subject treated according to the present disclosure has received a vaccine for a RSV and / or MPV and the vaccine is determined to be ineffective, e.g., by post-vaccine infection or symptoms in the subject, by clinical diagnosis or scientific or regulatory consensus. 30 Prophylaxis of infection with RSV and / or MPV refers in particular to prophylactic settings, wherein the subject was not diagnosed with infection with RSV and / or MPV virus (either no diagnosis was performed or diagnosis results were negative) and / or the subject does not show or experience symptoms of infection with RSV and / or MPV. Prophylaxis of infection with RSV and / or MPV is particularly useful in subjects at greater risk of infection,160587589.193 severe disease, or complications when infected, babies 12 months and younger (infants), especially premature infants, older adults, people with heart and lung disease, particularly congenital heart disease or chronic obstructive pulmonary (COPD), or anyone with a weak immune system (immunocompromised), asthma, or cancer, or who had a lung transplant. 5 In certain embodiments, treatment is administered as peri-exposure or pre-exposure prophylaxis. In therapeutic settings, in contrast, the subject is typically infected with a RSV and / or a MPV, diagnosed with RSV and / or MPV infection, and / or showing symptoms of RSV and / or MPV infection. Of note, the terms "treatment" and "therapy" / "therapeutic" of RSV and / or MPV 10 infection include (complete) cure as well as attenuation / reduction of RSV and / or MPV infection and / or related symptoms (e.g., attenuation / reduction of severity of infection and / or symptoms, number of symptoms, duration of infection and / or symptoms, or any combination thereof). It will be understood that reference herein to a reduced number and / or severity of 15 symptoms, which reduction results from administration of a presently disclosed pharmaceutical composition, describes a comparison with a reference subject who did not receive a disclosed pharmaceutical composition. A reference subject can be, for example, (i) the same subject during an earlier period of time (e.g., a prior RSV and / or MPV season), (ii) a subject of a same or a similar: age or age group; gender; pregnancy status; chronic medical condition (such as 20 chronic cardiac, pulmonary, renal, metabolic, neurodevelopmental, liver or hematologic diseases) or lack thereof; and / or immunosuppressive condition or lack thereof; or (iii) a typical subject within a population (e.g., local, regional, or national, including of a same or similar age or age range and / or general state of health) during a RSV and / or MPV virus season. Prophylaxis can be determined by, for example, the failure to develop a diagnosed RSV and / or 25 MPV infection and / or the lack of symptoms associated with RSV and / or MPV infection during a part of a full RSV and / or MPV season, or over a full RSV and / or MPV season. In certain embodiments, the methods provided herein include administering a therapeutically effective amount of a composition according to the present disclosure to a subject at immediate risk of RSV and / or MPV infection. 30 Typical routes of administering the presently disclosed compositions include, without limitation, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term "parenteral", as used herein, includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In certain embodiments, administering comprises administering by a route that is selected160587589.194 from oral, intravenous, parenteral, intragastric, intrapleural, intrapulmonary, intrarectal, intradermal, intraperitoneal, intratumoral, subcutaneous, topical, transdermal, intracisternal, intrathecal, intranasal, and intramuscular. In particular embodiments, a method comprises orally administering the antibody, antigen-binding fragment, polynucleotide, vector, host cell, or 5 composition to the subject. Pharmaceutical compositions according to certain embodiments of the present invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a subject or patient may take the form of one or more dosage units, where for 10 example, a tablet may be a single dosage unit, and a container of a herein described an antibody or antigen-binding in aerosol form may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition to be administered will, in any 15 event, contain an effective amount of an antibody or antigen-binding fragment, polynucleotide, vector, host cell, , or composition of the present disclosure, for treatment of a disease or condition of interest in accordance with teachings herein. A composition may be in the form of a solid or liquid. In some embodiments, the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form. 20 The carrier(s) may be liquid, with the compositions being, for example, an oral oil, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration. When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi solid, semi liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid. 25 As a solid composition for oral administration, the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like. Such a solid composition will typically contain one or more inert diluents or edible carriers. In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; 30 excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent. When the composition is in the form of a capsule, for example, a gelatin capsule, it160587589.195 may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil. The composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, 5 as two examples. When intended for oral administration, preferred compositions contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye / colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included. 10 Liquid pharmaceutical compositions, whether they be solutions, suspensions or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer’s solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; 15 antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred 20 adjuvant. An injectable pharmaceutical composition is preferably sterile. A liquid composition intended for either parenteral or oral administration should contain an amount of an antibody or antigen-binding fragment as herein disclosed such that a suitable dosage will be obtained. Typically, this amount is at least 0.01% of the antibody or antigen-binding fragment in the composition. When intended for oral administration, this 25 amount may be varied to be between 0.1 and about 70% of the weight of the composition. Certain oral pharmaceutical compositions contain between about 4% and about 75% of the antibody or antigen-binding fragment. In certain embodiments, pharmaceutical compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10% by weight of antibody or antigen-binding fragment prior to 30 dilution. The composition may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.160587589.196 Thickening agents may be present in a composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device. The pharmaceutical composition may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug. The 5 composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and polyethylene glycol. A composition may include various materials which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, 10 and may be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients may be encased in a gelatin capsule. The composition in solid or liquid form may include an agent that binds to the antibody or antigen-binding fragment of the disclosure and thereby assists in the delivery of the compound. Suitable agents that may act in this capacity include monoclonal or polyclonal antibodies, one or more proteins or a 15 liposome. The composition may consist essentially of dosage units that can be administered as an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols may be delivered in single phase, bi phasic, or tri phasic systems in order to deliver the active 20 ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One of ordinary skill in the art, without undue experimentation, may determine preferred aerosols. It will be understood that compositions of the present disclosure also encompass carrier molecules for polynucleotides, as described herein (e.g., lipid nanoparticles, nanoscale delivery 25 platforms, and the like). The pharmaceutical compositions may be prepared by methodology well known in the pharmaceutical art. For example, a composition intended to be administered by injection can be prepared by combining a composition that comprises an antibody, antigen-binding fragment, or antibody conjugate as described herein and optionally, one or more of salts, buffers and / or 30 stabilizers, with sterile, distilled water so as to form a solution. A surfactant may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the peptide composition so as to facilitate dissolution or homogeneous suspension of the antibody or antigen-binding fragment in the aqueous delivery system.160587589.197 In general, an appropriate dose and treatment regimen provide the composition(s) in an amount sufficient to provide therapeutic and / or prophylactic benefit (such as described herein, including an improved clinical outcome (e.g., a decrease in frequency, duration, or severity of diarrhea or associated dehydration, or inflammation, or longer disease-free and / or overall 5 survival, or a lessening of symptom severity). For prophylactic use, a dose should be sufficient to prevent, delay the onset of, or diminish the severity of a disease associated with disease or disorder. Prophylactic benefit of the compositions administered according to the methods described herein can be determined by performing pre-clinical (including in vitro and in vivo animal studies) and clinical studies and analyzing data obtained therefrom by appropriate 10 statistical, biological, and clinical methods and techniques, all of which can readily be practiced by a person skilled in the art. Compositions are administered in an effective amount (e.g., to RSV and / or MPV infection), which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the 15 age, body weight, general health, sex, and diet of the subject; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy. In certain embodiments, following administration of therapies according to the formulations and methods of this disclosure, test subjects will exhibit about a 10% up to about a 99% reduction in one or more symptoms 20 associated with the disease or disorder being treated as compared to placebo-treated or other suitable control subjects. Generally, a therapeutically effective dose of an antibody or antigen binding fragment is (for a 70 kg mammal) from about 0.001 mg / kg (i.e., 0.07 mg) to about 100 mg / kg (i.e., 7.0 g); preferably a therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg / kg (i.e., 25 0.7 mg) to about 50 mg / kg (i.e., 3.5 g); more preferably a therapeutically effective dose is (for a 70 kg mammal) from about 1 mg / kg (i.e., 70 mg) to about 25 mg / kg (i.e., 1.75 g). For polynucleotides, vectors, host cells, and related compositions of the present disclosure, a therapeutically effective dose may be different than for an antibody or antigen-binding fragment. 30 In certain embodiments, a method comprises administering the antibody, antigen- binding fragment, polynucleotide, vector, host cell, or composition to the subject at 2, 3, 4, 5, 6, 7, 8, 9, 10 times, or more. In certain embodiments, a method comprises administering the antibody, antigen- binding fragment, or composition to the subject a plurality of times, wherein a160587589.198 second or successive administration is performed at about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 24, about 48, about 74, about 96 hours, or more, following a first or prior administration, respectively. In certain embodiments, a method comprises administering the antibody, antigen- 5 binding fragment, polynucleotide, vector, host cell, or composition at least one time prior to the subject being infected by RSV and / or MPV. Compositions comprising an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition of the present disclosure may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents, 10 such as, for example, an antiviral, e.g., ribavirin or a monoclonal antibody, e.g. palivizumab. Such combination therapy may include administration of a single pharmaceutical dosage formulation which contains a compound of the invention and one or more additional active agents, as well as administration of compositions comprising an antibody or antigen-binding fragment of the disclosure and each active agent in its own separate dosage formulation. For 15 example, an antibody or antigen-binding fragment as described herein and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations. Similarly, an antibody or antigen-binding fragment as described herein and the other active agent can be administered to the subject together in a single parenteral dosage composition such as in a 20 saline solution or other physiologically acceptable solution, or each agent administered in separate parenteral dosage formulations. Where separate dosage formulations are used, the compositions comprising an antibody or antigen-binding fragment and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially and in any order; combination therapy is understood to 25 include all these regimens. In some embodiments, an antibody (or one or more nucleic acid, host cell, vector, or composition) is administered to a subject who has previously received one or more anti- inflammatory agent and / or one or more antiviral agent. In some embodiments, the antiviral is ribavirin. In some embodiments, one or more anti-inflammatory agent and / or one or more 30 antiviral agent is administered to a subject who has previously received an antibody (or one or more nucleic acid, host cell, vector, or composition). In some embodiments, the antiviral is a ribavirin. In some embodiments, an antibody, polynucleotide, vector, or composition as described herein is administered to prevent or treat a RSV infection only, or a MPV infection160587589.199 only. In such embodiments, the antibody may specifically bind only RSV or only MPV. In a related aspect, uses of the presently disclosed antibodies, antigen-binding fragments, vectors, host cells, and compositions (e.g., in the diagnosis, prophylaxis, and / or treatment of RSV and / or MPV infection, in the manufacture of a medicament for preventing or 5 treating RSV and / or MPV infection) are provided. In certain embodiments, an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition is provided for use in a method of treating a RSV and / or MPV infection in a subject. In some embodiments, the method of treating is a method of treating only RSV infection or MPV infection, not infection by both viruses. Antibodies identified 10 herein as binding only RSV or MPV and any related antigen-binding fragment, polynucleotide, vector, host cell, or composition may in particular be used in such embodiments. In certain embodiments, an antibody, antigen-binding fragment, or composition is provided for use in a method of manufacturing or preparing a medicament for treating RSV and / or MPV infection in a subject. In some embodiments, the medicament is for treating only 15 RSV infection or MPV infection, not infection by both viruses. Antibodies identified herein as binding only RSV or MPV and any related antigen-binding fragment, polynucleotide, vector, host cell, or composition may in particular be used in such embodiments. The present disclosure further provides a kit comprising one or more of any antibodies, antigen-binding fragments, polynucleotides, nucleic acids, vectors, or other compositions 20 disclosed herein. The kit may further include one or more of a container, such as a tube, vial, or syringe, an activator, a valve, a subcontainer, or instructions for use, such as for administering to a subject. The present disclosure also provides the following exemplary embodiments: 25 Embodiment 1. An antibody or antigen-binding fragment that is capable of binding to a respiratory syncytial virus (RSV) fusion glycoprotein (RSV-F), wherein the antibody or antigen-binding fragment comprises: (i) a heavy chain variable domain (VH) comprising the complementarity determining region (CDR)H1, CDRH2, and CDRH3 amino acid sequences of the VH or Fd 30 amino acid sequence set forth in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259,; and (ii) a light chain variable domain (VL) comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL or light chain (LC) amino acid sequence160587589.1100 set forth in any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, optionally wherein the antibody or antigen-binding fragment does not comprise all of 5 the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 amino acid sequences of MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5. Embodiment 2. The antibody or antigen-binding fragment of embodiment 1, wherein the antibody or antigen-binding fragment comprises: (i) a heavy chain variable domain (VH) 10 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259; and (ii) a light chain variable domain (VL) comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any 15 one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260. Embodiment 3. The antibody or antigen-binding fragment of embodiment 1 or 2, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 2, and a VL 20 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (c) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 3, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (d) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 4, 25 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (e) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 5, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (f) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 6, 30 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (g) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 7, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (h) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.1101 ID NO: 8, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (i) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 10, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 5 (j) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 11, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (k) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 12, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 10 (l) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 13, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (m) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 14, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 15 (n) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 15, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (o) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 15, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 20 (p) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 16, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (q) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 17, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 25 (r) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 18, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (s) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 19, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 30 (t) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:20, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (u) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 21, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.1102 ID NO: 94; (v) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 22, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (w) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 23, 5 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (x) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 24, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (y) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 25, 10 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (z) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 26, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (aa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 27, 15 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (bb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 28, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (cc) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 29, 20 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (dd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 30, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ee) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 31, 25 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ff) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 32, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (gg) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 33, 30 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (hh) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 34, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ii) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.1103 ID NO: 35, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (jj) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 36, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 5 (kk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 37, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 38, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 10 (mm) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 39, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (nn) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 40, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 15 (oo) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 41, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (pp) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 42, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 20 (qq) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 43, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (rr) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 44, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 25 (ss) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 45, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (tt) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 46, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; 30 (uu) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 47, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (vv) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 48, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ160587589.1104 ID NO: 94; (ww) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 49, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (xx) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 50, 5 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (yy) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 51, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (zz) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 52, 10 and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (aaa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 53, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (bbb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ 15 ID NO: 54, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ccc) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 55, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ddd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 20 forth in SEQ ID NO: 56, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (eee) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 57, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (fff) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 25 forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 59; (ggg) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 61; (hhh) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set 30 forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 62; (iii) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 63; (jjj) a VH comprising, consisting essentially of, or consisting of the amino acid160587589.1105 sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 64; (kkk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set 5 forth in SEQ ID NO: 65; (lll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ...

Claims

CLAIMS What is claimed is:

1. An antibody or antigen-binding fragment that is capable of binding to a respiratory syncytial virus (RSV) fusion glycoprotein (RSV-F), wherein the antibody or antigen-binding fragment comprises: (i) a heavy chain variable domain (VH) comprising the complementarity determining region (CDR)H1, CDRH2, and CDRH3 amino acid sequences of the VH or Fd amino acid sequence set forth in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259,; and (ii) a light chain variable domain (VL) comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL or light chain (LC) amino acid sequence set forth in any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260, optionally wherein the antibody or antigen-binding fragment does not comprise all of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 amino acid sequences of MPK190, MPK190-v.1.1, MPK190-v1.3, MPK65-v2-v1.2, MPK65-v2-v3.1, MPK 176-v1.3, MPK176-v4.3, MPK201-v1.2, MPK201-v4.1, or RSD5.

2. The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment comprises: (i) a heavy chain variable domain (VH) comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.: 1-8, 10-28, 30-57, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 240, 242, 244, 246, 247, 248, 249, 251, 253, 255, 257, and 259; and (ii) a light chain variable domain (VL) comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.: 59, 61-74, 76, 77, 79, 81-84, 86-89, 94, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 241, 243, 245, 250, 252, 254, 256, 258, and 260.

3. The antibody or antigen-binding fragment of claim 1 or 2, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 2, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ0587589.1220ID NO: 94; (c) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 3, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (d) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 4, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (e) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 5, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (f) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 6, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (g) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 7, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (h) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 8, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (i) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 10, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (j) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 11, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (k) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 12, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (l) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 13, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (m) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 14, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (n) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 15, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (o) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 15, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (p) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ0587589.1221ID NO: 16, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (q) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 17, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (r) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 18, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (s) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 19, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (t) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:20, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (u) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 21, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (v) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 22, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (w) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 23, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (x) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 24, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (y) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 25, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (z) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 26, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (aa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 27, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (bb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 28, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (cc) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 29, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ0587589.1222ID NO: 94; (dd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 30, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ee) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 31, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ff) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 32, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (gg) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 33, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (hh) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 34, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ii) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 35, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (jj) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 36, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (kk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 37, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 38, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (mm) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 39, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (nn) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 40, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (oo) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 41, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (pp) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 42, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (qq) a VH comprising, consisting essentially of, or consisting of the amino acid0587589.1223sequence set forth in SEQ ID NO: 43, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (rr) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 44, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ss) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 45, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (tt) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 46, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (uu) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 47, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (vv) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 48, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ww) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 49, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (xx) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 50, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (yy) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 51, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (zz) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 52, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (aaa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 53, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (bbb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 54, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ccc) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 55, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (ddd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 56, and a VL comprising, consisting essentially of, or0587589.1224consisting of the amino acid sequence set forth in SEQ ID NO: 94; (eee) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 57, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (fff) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 59; (ggg) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 61; (hhh) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 62; (iii) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 63; (jjj) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 64; (kkk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 65; (lll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 66; (mmm) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 67; (nnn) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 68; (ooo) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 69; (ppp) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 70; (qqq) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 71; (rrr) a VH comprising, consisting essentially of, or0587589.1225consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 72; (sss) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 73; (ttt) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 74; (uuu) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 76; (vvv) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 77; (www) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 79; (xxx) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 81; (yyy) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 82; (zzz) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 83; (aaaa) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 84; (bbbb) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 86; (cccc) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 87; (dddd) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 88; (eeee) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting0587589.1226essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 89; (ffff) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 91; (jjjj) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 133, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 165; (kkkk) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 115, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (llll) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 115, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 165; (mmmm) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 111, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 165; (nnnn) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 133, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 94; (oooo) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 240, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 241; (pppp) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 242, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 243; (qqqq) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 244, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 245; (rrrr) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 246, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 245; (ssss) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 247, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 245; (tttt) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 248, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 243; (uuuu) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 249, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set0587589.1227forth in SEQ ID NO: 250; (vvvv) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 251, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 252; (wwww) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 253, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 254; (xxxx) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 255, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 256; (yyyy) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 257, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 258; or (zzzz) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 259, and a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

260.

4. The antibody or antigen-binding fragment of any one of claims 1-3, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 are according to: (i) the IMGT numbering system; (ii) the CCG numbering system; (iii) the Kabat numbering system; (iv) the Chothia numbering system; (v) the Martin (Enhanced Chothia) numbering system; (vi) the AbM numbering system; (vii) the AHo numbering system; (viii) the Contact numbering system; or (ix) a combination of any two or more of the numbering systems set forth in (i)-(viii), optionally wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 are according to the IMGT numbering system.

5. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:251, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

252.

6. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:240, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in0587589.1228SEQ ID NO:

241.

7. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:247, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

245.

8. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:242, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

243.

9. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:244, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

245.

10. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:255, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

256.

11. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:253, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

254.

12. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID0587589.1229NO:257, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

258.

13. The antibody or antigen-binding fragment of any one of claims 1-4, wherein the antibody or antigen-binding fragment comprises: (a) a VH comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:259, and (b) a VL comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

260.

14. The antibody or antigen-binding fragment of any one of claims 1-13, wherein the antibody or antigen-binding fragment thereof comprises a CH1 domain and / or a CL domain.

15. The antibody or antigen-binding fragment of claim 14, wherein the CL domain is a lambda CL domain or a kappa CL domain.

16. The antibody or antigen-binding fragment thereof of any one of claims 1-15, wherein the antibody or antigen-binding fragment is capable of binding to a metapneumovirus fusion protein (MPV-F), optionally a MPV-F that comprises a D280N mutation (MPV-F N280).

17. The antibody or antigen-binding fragment thereof of any one of claims 1-16, wherein the antibody or antigen-binding fragment is a IgG, IgA, IgM, IgE, or IgD isotype, wherein, optionally, the antibody or antigen-binding fragment is a IgG isotype selected from IgG1, IgG2, IgG3, and IgG4, and is preferably IgG1.

18. The antibody or antigen-binding fragment thereof of any one of claims 1-17, wherein the antibody or antigen-binding fragment thereof is a G1m17,1 allotype, G1m3 allotype, or G1m3,1 allotype.

19. The antibody or antigen-binding fragment of any one of claims 1-18, wherein the antibody, or the antigen-binding fragment, comprises a human antibody, a monoclonal antibody, a purified antibody, a single chain antibody, a Fab, a Fab’, a F(ab’)2, or Fv.

20. The antibody or antigen-binding fragment of any one of claims 1-19, wherein the antibody or antigen-binding fragment is a multi-specific antibody or antigen-binding fragment, optionally a bispecific antibody or antigen-binding fragment.0587589.123021. The antibody or antigen-binding fragment of any one of claims 1-20, wherein the antibody or antigen-binding fragment comprises a Fc polypeptide or a fragment thereof.

22. The antibody or antigen-binding fragment of claim 21, wherein the Fc polypeptide or fragment comprises: a mutation that enhances binding to a FcRn as compared to a reference Fc polypeptide that does not comprise the mutation; (ii) a mutation that enhances binding to a FcγR as compared to a reference Fc polypeptide that does not comprise the mutation; (iii) a mutation that enhances binding to human FcγRIIa and / or decreases binding to a human FcγRIIb as compared to a reference Fc polypeptide that does not comprise the mutation; and / or (iv) a mutation that enhances binding to a human C1q compared to a reference Fc polypeptide that does not comprise the mutation.

23. The antibody or antigen-binding fragment of any one of claims 21 or 22, wherein the Fc polypeptide comprises the substitution mutations M428L / N434S, M428L / N434A, G236A / A330L / I332E / M428L / N434S, or G236A / A330L / I332E / M428L / N434A, wherein, optionally, the antibody or antigen-binding fragment is an IgG1 isotype, and, further optionally, comprises or consists of a Fc polypeptide or fragment thereof that comprises or consists of amino acid sequences having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any one of SEQ ID NOs: 498-536, or that comprises or consists of, the amino acid sequences set forth in any one of SEQ ID NOs: 498-536.

24. The antibody or antigen-binding fragment of any one of claims 21-23, wherein the Fc polypeptide comprises the substitution mutation M252Y / S254T / T256E.

25. The antibody or antigen-binding fragment of claim 24, wherein the Fc polypeptide comprises any one of SEQ ID NOS:580-582, 594-601.0587589.123126. The antibody or antigen-binding fragment thereof of claim 5, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 584; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

585.

27. The antibody or antigen-binding fragment thereof of claim 6, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 190; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

191.

28. The antibody or antigen-binding fragment thereof of claim 7, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 197; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

195.

29. The antibody or antigen-binding fragment thereof of claim 8, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 192; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

193.

30. The antibody or antigen-binding fragment thereof of claim 9, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 194; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 195.0587589.123231. The antibody or antigen-binding fragment thereof of claim 10, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 588; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

589.

32. The antibody or antigen-binding fragment thereof of claim 11, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 586; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

587.

33. The antibody or antigen-binding fragment thereof of claim 12, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 590; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

591.

34. The antibody or antigen-binding fragment thereof of claim 13, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 592; and (b) a light chain comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:

593.

35. An antibody or antigen-binding fragment that is capable of binding to a respiratory syncytial virus (RSV) fusion glycoprotein (RSV-F), wherein the antibody or antigen-binding fragment comprises the VH and VL, and optionally the CH1 and the CL, of any one of antibodies ML-190-1 to ML-190-90 (i.e., ML-190-1 or ML-190-2 or ML-190-3 … or ML-190-90) as set forth in Table 1 and Table 2.0587589.123336. The antibody or antigen-binding fragment of any one of claims 1-35, wherein the antibody is capable of neutralizing infection by a RSV and / or MPV.

37. The antibody or antigen-binding fragment of any one of claims 1-36, wherein the antibody or antigen-binding fragment is capable of treating and / or preventing (i) a RSV infection and / or (ii) a MPV infection in a subject.

38. An isolated polynucleotide encoding the antibody or antigen-binding fragment of any one of claims 1-37, or encoding a VH, a heavy chain, a VL, a light chain and / or at least one CDR of the antibody or the antigen-binding fragment.

39. The polynucleotide of claim 38, wherein the polynucleotide is codon optimized for expression in a host cell.

40. A recombinant vector comprising the polynucleotide of claim 38 or 39.

41. A host cell comprising the polynucleotide of claim 38 or 39 and / or the vector of claim 40, wherein the polynucleotide is heterologous to the host cell and wherein the host cell is capable of expressing the encoded antibody or antigen-binding fragment.

42. A composition comprising: (i) the antibody or antigen-binding fragment of any one of claims 1-37; (ii) the polynucleotide of claim 38 or 39; (iii) the recombinant vector of claim 40; and / or (iv) the host cell of claim 41; and a pharmaceutically acceptable excipient, carrier, or diluent.

43. A method of making an antibody or antigen-binding fragment of any one of claims 1-37, comprising culturing the host cell of claim 41 for a time and under conditions sufficient for the host cell to express the antibody or antigen-binding fragment, optionally wherein the method further comprises an isolation and / or purification step.0587589.123444. A method of treating or preventing a RSV infection and / or a MPV infection in a subject, the method comprising administering to the subject an effective amount of: (i) the antibody or antigen-binding fragment of any one of claims 1-37; (ii) the polynucleotide of claim 38 or 39; (iii) the recombinant vector of claim 40; (iv) the host cell of claim 41; and / or (v) the composition of claim 42.

45. The method of claim 44, wherein the treatment and / or prevention comprises post-exposure prophylaxis.

46. The method of claim 44 or 45, wherein the subject has received, is receiving, or will receive an antiviral.

47. The method of claim 44, wherein the subject has received pre-exposure prophylaxis treatment.

48. The antibody or antigen-binding fragment of any one of claims 1-37, the polynucleotide of claim 38 or 39, the recombinant vector of claim 40, the host cell of claim 41, and / or the composition of claim 42, for use in a method of treating or preventing a RSV infection and / or a MPV infection in a subject, optionally wherein the subject is an infant.

49. The antibody or antigen-binding fragment of any one of claims 1-37, the polynucleotide of claim 38 or 39, the recombinant vector of claim 40, the host cell of claim 41, and / or the composition of claim 42, for use in the preparation of a medicament for the treatment or prevention of a RSV infection and / or an MPV infection in a subject, optionally wherein the subject is an infant.

50. A method for in vitro diagnosis of a RSV infection and / or a MPV infection, the method comprising: (i) contacting a sample from a subject with an antibody or antigen-binding fragment of any one of claims 1-37; and (ii) detecting a complex comprising an antigen and the antibody, or comprising an antigen and the antigen-binding fragment.0587589.123551. The method of any one of claims 44-47, wherein the subject is an infant.

52. A kit comprising a liquid composition comprising and antibody or antigen- binding fragment of any one of claims 1-37, a polynucleotide according to claim 38 or 39, a recombinant vector according to claim 40, a host cell according to claim 41, or a composition according to claim 42 and instructions for use thereof in treating or preventing an RSV infection and / or a MPV infection in a subject.0587589.1236

Images